var title_f39_14_40160="Taking uteroovarian pedicle";
var content_f39_14_40160=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Taking uteroovarian pedicle during laparoscopic hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Lyons, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_14_40160=[""].join("\n");
var outline_f39_14_40160=null;
var title_f39_14_40161="Patient information: Rosacea (The Basics)";
var content_f39_14_40161=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16652\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/32/36353\">",
"         Rosacea",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/45/5843\">",
"          Rosacea",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/12/1218\">",
"         Patient information: Acne (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?19/40/20099\">",
"         Patient information: Acne (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Rosacea (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/rosacea-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H29421727\">",
"      <span class=\"h1\">",
"       What is rosacea?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Rosacea is a skin condition that causes redness and raised, red bumps on the cheeks, nose, chin, forehead, or eyelids. Rosacea is a long-term condition that will get worse over time if it is not treated.",
"     </p>",
"     <p>",
"      Rosacea happens most often in adults ages 30 to 60.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29421742\">",
"      <span class=\"h1\">",
"       What are the symptoms of rosacea?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Rosacea affects the cheeks, nose, chin, forehead, or eyelids. Symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Redness (",
"        <a class=\"graphic graphic_picture graphicRef79905 \" href=\"mobipreview.htm?35/32/36353\">",
"         picture 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Blushing easily",
"       </li>",
"       <li>",
"        Raised, red bumps with or without pus in them (",
"        <a class=\"graphic graphic_picture graphicRef60054 \" href=\"mobipreview.htm?5/45/5843\">",
"         picture 2",
"        </a>",
"        ) &ndash; Bumps from rosacea can sometimes look like acne, but they aren&rsquo;t acne.",
"       </li>",
"       <li>",
"        Tiny, swollen blood vessels on the skin (called &ldquo;telangiectasias&rdquo;)",
"       </li>",
"       <li>",
"        A burning or gritty feeling in the eyes",
"       </li>",
"       <li>",
"        A red, swollen, and rounded nose",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Sometimes, people&rsquo;s symptoms are under control. Other times, people&rsquo;s symptoms worsen and flare up. Flare-ups are usually caused by &ldquo;triggers,&rdquo; which are things that make symptoms worse. Common triggers include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Eating hot or spicy foods, or drinking hot drinks",
"       </li>",
"       <li>",
"        Drinking alcohol",
"       </li>",
"       <li>",
"        Being too hot or cold",
"       </li>",
"       <li>",
"        Sunlight",
"       </li>",
"       <li>",
"        Stress and other strong emotions",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29421757\">",
"      <span class=\"h1\">",
"       Is there a test for rosacea?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. There is no test. But your doctor or nurse should be able to tell if you have it by learning about your symptoms and doing an exam. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29421772\">",
"      <span class=\"h1\">",
"       How is rosacea treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment for rosacea has 2 parts. The treatments do not cure rosacea, but they help control symptoms and prevent flare-ups.",
"     </p>",
"     <p>",
"      Treatment involves both:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medicines &ndash; Doctors can use different medicines to treat rosacea. The medicines can come as gels, creams, or lotions that go on your skin, or as pills that you swallow. You will likely need to take or use medicines for a long time.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Lifestyle changes &ndash; To help control your symptoms and prevent flare-ups, you should:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Avoid the common triggers listed above and any other triggers that you know worsen your symptoms",
"       </li>",
"       <li>",
"        Use mild, unscented face cleansers to wash your face",
"       </li>",
"       <li>",
"        Wear sunscreen every day",
"       </li>",
"       <li>",
"        Avoid using products on your face with alcohol, acid, or other ingredients that could bother your skin",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29421787\">",
"      <span class=\"h1\">",
"       What if my symptoms are severe or don&rsquo;t get better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your symptoms are severe or don&rsquo;t get better with treatment, you will probably need to see a skin specialist (called a dermatologist). The specialist will talk with you about other possible treatments.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29421802\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to get pregnant, talk with your doctor or nurse. Some medicines for rosacea are not safe to take during pregnancy. Your doctor or nurse will make sure that your medicine is safe to take.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29421816\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/12/1218?source=see_link\">",
"       Patient information: Acne (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/40/20099?source=see_link\">",
"       Patient information: Acne (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/14/40161?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16652 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-062E1C4994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_14_40161=[""].join("\n");
var outline_f39_14_40161=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29421727\">",
"      What is rosacea?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29421742\">",
"      What are the symptoms of rosacea?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29421757\">",
"      Is there a test for rosacea?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29421772\">",
"      How is rosacea treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29421787\">",
"      What if my symptoms are severe or don&rsquo;t get better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29421802\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29421816\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16652\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/32/36353\">",
"      Rosacea",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/45/5843\">",
"       Rosacea",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/40/20099?source=related_link\">",
"      Patient information: Acne (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/12/1218?source=related_link\">",
"      Patient information: Acne (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_14_40162="Creation of esophagojejunostomy";
var content_f39_14_40162=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F63448&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F63448&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Creation of esophagojejunostomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 716px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    To create the esophagojejunostomy, the anvil of a number 25 end-to-end anastomosis (EEA) stapling device is secured in the distal esophagus and a retrocolic Roux-en-Y esophagojejunostomy is fashioned through the transverse mesocolon using a jejunal limb approximately 40 cm from the Ligament of Treitz.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_14_40162=[""].join("\n");
var outline_f39_14_40162=null;
var title_f39_14_40163="Epinephrine (adrenaline) (nasal): Pediatric drug information";
var content_f39_14_40163=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Epinephrine (adrenaline) (nasal): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?3/34/3620?source=see_link\">",
"    see \"Epinephrine (adrenaline) (nasal): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/59/4020?source=see_link\">",
"    see \"Epinephrine (adrenaline) (nasal): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8084972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Adrenalin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8090006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Adrenalin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10484205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Decongestant, Nasal",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10484207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?3/34/3620?source=see_link\">",
"      see \"Epinephrine (adrenaline) (nasal): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;6 years and Adults: Apply drops locally as needed; do not exceed 1 mL every 15 minutes",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8085184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal, as hydrochloride [drops/spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adrenalin&reg;: 1 mg/mL (30 mL) [contains chlorobutanol, sodium bisulfite; 1:1000]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8084991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10484208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Apply as drops or with sterile swab.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10484206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nasal decongestant, decrease superficial hemorrhage",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8084970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       EPINEPHrine may be confused with ePHEDrine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8085028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, cardiac arrhythmia, chest pain, flushing, hypertension, pallor, palpitation, sudden death, tachycardia (parenteral), vasoconstriction, ventricular ectopy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety (transient), apprehensiveness, cerebral hemorrhage, dizziness, headache, insomnia, lightheadedness, nervousness, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Dry throat, loss of appetite, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Acute urinary retention in patients with bladder outflow obstruction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Allergic lid reaction, burning, eye pain, ocular irritation, precipitation of or exacerbation of narrow-angle glaucoma, transient stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, pulmonary edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F11432224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to epinephrine or any component; concurrent use or within 2 weeks of MAO inhibitors",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10484985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with diabetes mellitus or cardiovascular disease (coronary artery disease, hypertension, diabetes mellitus, Parkinson&rsquo;s disease, thyroid disease, or cerebrovascular disease. Use with extreme caution in patients taking MAO inhibitors and tricyclic antidepressants; effects of epinephrine may be potentiated. Rebound nasal congestion may occur after frequent nasal use.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11432225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products contain sulfites as preservatives which may cause allergic reactions in susceptible individuals; the presence of sulfites in some products (eg, EpiPen&reg; and Twinject&reg;) should not deter administration during a serious allergic or other emergency situation even if the patient is sulfite-sensitive. Due to direct catecholamine effect, administration of epinephrine may cause high arterial blood pressure (may cause angina pectoris, aortic rupture, or cerebral hemorrhage); induce potentially serious cardiac arrhythmias; and produce constriction of renal blood vessels and decrease urine formation initially (with parenteral administration)",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of COMT",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8085030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems. Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May decrease the metabolism of COMT Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: May enhance the arrhythmogenic effect of EPINEPHrine (Nasal).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Primarily with oral administration of phenylephrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Promethazine: May diminish the vasoconstricting effect of EPINEPHrine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8084996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to the EPINEPHrine (Systemic) monograph.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10484209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10484987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates alpha-, beta",
"     <sub>",
"      1",
"     </sub>",
"     - and beta",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic receptors, resulting in local vasoconstriction and relief of nasal congestion",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10484989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local vasoconstriction (topical):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: 5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: &lt;1 hour",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10484990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Crosses placenta but not blood-brain barrier",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Extensive in the liver and other tissues by the enzymes catechol-o-methyltransferase and monoamine oxidase",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15974 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-1E842E28B5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_14_40163=[""].join("\n");
var outline_f39_14_40163=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8084972\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090006\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484205\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484207\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085184\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8084991\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484208\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484206\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8084970\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085028\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11432224\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484985\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11432225\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299270\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085030\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8084996\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484209\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484987\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484989\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484990\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15974\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15974|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?3/34/3620?source=related_link\">",
"      Epinephrine (adrenaline) (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/59/4020?source=related_link\">",
"      Epinephrine (adrenaline) (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/4/11337?source=related_link\">",
"      Epinephrine (adrenaline) (systemic therapy and oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/24/10630?source=related_link\">",
"      Epinephrine (adrenaline) (systemic therapy and oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/20/10568?source=related_link\">",
"      Epinephrine (adrenaline) (systemic therapy and oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_14_40164="Pilar cyst 2";
var content_f39_14_40164=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F66512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F66512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pilar cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_14_40164=[""].join("\n");
var outline_f39_14_40164=null;
var title_f39_14_40165="Tacrolimus (systemic): Patient drug information";
var content_f39_14_40165=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tacrolimus (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4778?source=see_link\">",
"     see \"Tacrolimus (systemic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?4/51/4921?source=see_link\">",
"     see \"Tacrolimus (systemic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9559510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hecoria&trade;;",
"     </li>",
"     <li>",
"      Prograf&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9559511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Advagraf&reg;;",
"     </li>",
"     <li>",
"      Prograf&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may add to your chance of getting lymphoma or other cancers.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700487",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad infections have happened in patients who take this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to keep the body from harming the organ after an organ transplant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat diseases of the immune system.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tacrolimus or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696837",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids, cholestyramine, or colestipol within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid grapefruit and grapefruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney function that gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698359",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sunburn.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More trips to the bathroom, more thirst, or weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Capsule:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Always take with food or always take on an empty stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Capsule:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12308 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-118.97.94.19-F0314D4D48-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_14_40165=[""].join("\n");
var outline_f39_14_40165=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559510\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559511\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029371\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029373\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029372\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029377\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029378\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029380\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029375\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029376\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029381\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029382\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4778?source=related_link\">",
"      Tacrolimus (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?4/51/4921?source=related_link\">",
"      Tacrolimus (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?6/30/6630?source=related_link\">",
"      Tacrolimus (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/21/341?source=related_link\">",
"      Tacrolimus (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/9/26772?source=related_link\">",
"      Tacrolimus (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_14_40166="Discoid LE of the scalp";
var content_f39_14_40166=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F53535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F53535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Discoid lupus of the scalp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 488px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Discoid lupus affecting the scalp and face is shown. Note the discoid plaques over eyebrows, forehead, and scalp, with post inflammatory peripheral hyperpigmentation and central scarring, resulting in alopecia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; 2012 American College of Rheumatology. Used with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_14_40166=[""].join("\n");
var outline_f39_14_40166=null;
var title_f39_14_40167="Virology, pathogenesis, and epidemiology of human herpesvirus 6 infection";
var content_f39_14_40167=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Virology, pathogenesis, and epidemiology of human herpesvirus 6 infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/14/40167/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/14/40167/contributors\">",
"     Cecile Tremblay, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/14/40167/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/14/40167/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/14/40167/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/14/40167/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/14/40167/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human herpesvirus 6 (HHV-6) was first isolated and characterized from patients with lymphoproliferative disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/1\">",
"     1",
"    </a>",
"    ] and was originally named human B-lymphotropic virus. Its name was changed to human herpesvirus 6 as its tropism was further characterized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The virology, pathogenesis, and epidemiology of HHV-6 infection will be discussed here. The clinical manifestations, diagnosis, and treatment in adults and children are presented separately; HHV-6 infection in hematopoietic cell transplant recipients is also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/1/10265?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of human herpesvirus-6 infection in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31577?source=see_link\">",
"     \"Human herpesvirus 6 infection in children: Clinical manifestations; diagnosis; and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/40/30346?source=see_link\">",
"     \"Human herpesvirus 6 infection in hematopoietic cell transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VIROLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-6 is a member of the herpesviridae family. Its genetic and biologic similarities to human cytomegalovirus (CMV) have prompted its classification in the beta herpesvirus subfamily (genus Roseolovirus, along with human herpesvirus 7 [HHV-7]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/3\">",
"     3",
"    </a>",
"    ]. As with other herpes viruses, mature HHV-6 virions are double-stranded DNA viruses, approximately 200 nm in diameter and are composed of four main structural elements: an electron-dense core, a capsid with icosahedral symmetry, a tegument, and an outer envelope.",
"   </p>",
"   <p>",
"    Two variants of HHV-6, HHV-6A and HHV-6B, differ in epidemiology, growth properties, nucleotide sequences, antigenic properties, and restriction endonuclease profiles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. The nucleotide sequence identity between the two variants ranges from 75 to 95 percent depending upon which gene is compared.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cell tropism",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-6 replicates most efficiently in vitro in activated primary T cells as well as in continuous T cell lines. However, the virus can also replicate with varying efficiency in a wide array of host cell types including",
"    <span class=\"nowrap\">",
"     monocytes/macrophages,",
"    </span>",
"    natural killer cells, astrocytes, megakaryocytes and glial cell lineages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/2,8-11\">",
"     2,8-11",
"    </a>",
"    ]. HHV-6 can also be recovered in vivo from a broad range of tissues such as lymph nodes, peripheral blood mononuclear cells (PBMCs), renal tubular cells, salivary glands, and the central nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/12-18\">",
"     12-18",
"    </a>",
"    ]. HHV-6 has also been identified in astrocytes from gliomas, suggesting a potential role in tumorigenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During acute HHV-6 infection,",
"    <span class=\"nowrap\">",
"     monocytes/macrophages",
"    </span>",
"    harbor more replication-competent HHV-6 than CD4+ T cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/21\">",
"     21",
"    </a>",
"    ]. Hematopoietic differentiation can also lead to HHV-6 reactivation from infected peripheral blood progenitor cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Viral replication",
"    </span>",
"    &nbsp;&mdash;&nbsp;CD46, an immunomodulatory protein that is also called membrane cofactor protein, is a cellular receptor for HHV-6A and HHV-6B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/23\">",
"     23",
"    </a>",
"    ]. The following observations have been made concerning this relationship:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both acute infection and cell fusion mediated by HHV-6 are specifically inhibited by antibodies against CD46, while fusion can be blocked competitively by soluble CD46 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nonhuman cells that are resistant to HHV-6 fusion and entry become susceptible upon expression of recombinant human CD46 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Three HHV-6 glycoproteins form a heterotrimeric complex on the viral envelope that is a viral ligand for human CD46 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether binding to CD46 plays a role in the immune dysfunction observed after HHV-6 infection remains to be determined. HHV-6 downregulates interleukin (IL)-12 production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/25\">",
"     25",
"    </a>",
"    ], an effect that may be mediated by crosslinking of CD46 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HHV-6 integrates into the human genome; seven different chromosomal sites of integration have been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/27\">",
"     27",
"    </a>",
"    ]. Mature HHV-6 virions are found within multivesicular bodies and are released from the host cell via the exosomal pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Effect on the immune system",
"    </span>",
"    &nbsp;&mdash;&nbsp;CD4+ T cells constitute the major population of cells permissive to HHV-6 replication even though HHV-6 does not bind directly to the CD4 molecule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/29\">",
"     29",
"    </a>",
"    ]. Once HHV-6 enters a permissive host cell, viral replication occurs relatively slowly. Within 24 hours after infection, the rate of cellular protein synthesis is high; by 65 hours after infection, host cell DNA synthesis is shut off and viral DNA synthesis is underway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/30\">",
"     30",
"    </a>",
"    ]. Cytopathic effects can be seen within three to five days after infection. The net effect is a significant impairment in immune function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/25\">",
"     25",
"    </a>",
"    ], which may be mediated in part by downregulation of cell surface CD3 expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/31\">",
"     31",
"    </a>",
"    ] or via induction of cytokines, such as tumor necrosis factor-alpha, interferon gamma, and interleukin-1 beta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HHV-6 differentially influences the functions of na&iuml;ve T cells and different subsets of memory CD4+ and CD8+ T cells, which may be due in part to differential susceptibility to HHV-6A-induced apoptosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/33\">",
"     33",
"    </a>",
"    ]. HHV-6 can be transmitted from monocyte-derived dendritic cells to stimulated CD4+ T cells in vitro. Thus, dendritic cells may be the first cell population targeted by HHV-6 and they could play an important role in the virus' transmission to T cells, which leads to further virus propagation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HHV-6 can induce expression of a superantigen, which may lead to further dysregulation of the immune system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/35\">",
"     35",
"    </a>",
"    ]. On the other hand, HHV-6 increases the activity of natural killer (NK) cells via activation of IL-15 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/36\">",
"     36",
"    </a>",
"    ]. The increase in NK cell activity may represent a natural antiviral defense mechanism that promotes elimination of virus-infected cells.",
"   </p>",
"   <p>",
"    HHV-6 may also establish a latent state in monocytes, capable of later reactivation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/14,37\">",
"     14,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Viral genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genome of the U1102 strain of HHV-6A has been completely sequenced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. HHV-6 replication genes encode a number of viral proteins including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      U38, a viral DNA polymerase",
"     </li>",
"     <li>",
"      U27, a polymerase",
"      <span class=\"nowrap\">",
"       accessory/processivity",
"      </span>",
"      protein",
"     </li>",
"     <li>",
"      U41, a single-stranded DNA binding protein",
"     </li>",
"     <li>",
"      U43, U74, U77, which are three helicase-primase proteins",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    HHV-6 also encodes three homologues of herpes simplex virus (HSV)-1 glycoproteins important in viral entry: gB, gH and gL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/54/29544?source=see_link\">",
"     \"Pathogenesis of herpes simplex virus type 1 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another candidate for a potential receptor-binding protein is gp82-105 which is a major component of virions and is a target for neutralizing antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/40\">",
"     40",
"    </a>",
"    ]. The possible effects of other genes are beyond the scope of this discussion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/38,41,42\">",
"     38,41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HHV-6 also encodes gene products that are able to transactivate human immunodeficiency virus (HIV)-1 long terminal repeat (LTR)- directed gene expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/43\">",
"     43",
"    </a>",
"    ]. This is particularly relevant because both HHV-6 and HIV-1 can infect CD4+ T lymphocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/44\">",
"     44",
"    </a>",
"    ] and HHV-6 induces CD4 expression in otherwise CD4 negative subpopulations of lymphocytes and natural killer cells, making them susceptible to HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/1/10265?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical manifestations, diagnosis, and treatment of human herpesvirus-6 infection in adults\", section on 'Lack of interaction with HIV'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-6 seroprevalence rates vary from 20 percent among pregnant women in Morocco [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/46\">",
"     46",
"    </a>",
"    ] to 100 percent among asymptomatic Chinese adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/47\">",
"     47",
"    </a>",
"    ]. In industrialized nations such as the United States and Japan, rates of seroprevalence range from 72 to 95 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HHV-6 is frequently acquired by an early age. This is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 2235 infants and children under the age of three who presented to the emergency department with an acute illness, HHV-6 DNA was detected in 10 percent of infants less than one month of age, consistent with perinatal transmission, compared with 66 percent at one year (",
"      <a class=\"graphic graphic_figure graphicRef57693 \" href=\"mobipreview.htm?26/45/27358\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/37\">",
"       37",
"      </a>",
"      ]. The rate of seroconversion was highest between 6 and 12 months of age.",
"     </li>",
"     <li>",
"      Similar findings were noted in a prospective study of 277 children in which saliva was tested weekly for HHV-6 DNA with the use of PCR during the first two years of life [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/50\">",
"       50",
"      </a>",
"      ]. Primary HHV-6 infection occurred in 130 children; 40 percent of infections occurred by 12 months of age, and 77 percent by 24 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Distribution of virus variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular techniques have been used to determine whether the distribution of the two HHV-6 variants differs based upon geography. Among young children with an acute febrile illness, the proportion of cases in which HHV-6A is detected in peripheral blood mononuclear cells (PBMCs) has varied from less than 3 percent in the United States to 44 percent of infants from central Africa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vast majority of isolates from otherwise healthy children or adults belong to subtype B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/37\">",
"     37",
"    </a>",
"    ]. In contrast, both subtypes A and B have been recovered from PBMCs of patients who are immunocompromised or chronically ill. In one study, for example, HHV-6A was the predominant HHV-6 variant in lymph nodes from HIV-1 infected adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/53\">",
"     53",
"    </a>",
"    ]. HHV-6A may also have greater neurotropism and neurovirulence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Incubation period and transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are few data regarding the incubation period of HHV6 infection, it is thought to be approximately 9 days (range 5 to 15 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common route of HHV-6 transmission appears to be transfer via saliva from mother to infant. Early studies detected HHV-6 in the saliva of almost all subjects tested, although some of the positive results might have been due to cross-reactivity with HHV-7 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/47,58\">",
"     47,58",
"    </a>",
"    ], which is shed in saliva much more frequently [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/59\">",
"     59",
"    </a>",
"    ]. The following observations have been made in later studies using PCR in healthy individuals, although cross-reactivity is still possible with some primers:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HHV-6 has been isolated from saliva in 3 to 90 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/13,59,60\">",
"       13,59,60",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      HHV-6 has been found in 63 percent of salivary gland biopsies, which appears to act as a viral reservoir [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/59\">",
"       59",
"      </a>",
"      ]. The tonsils may be another common site of latent infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Perinatal transmission is also possible. Most women of reproductive age have been infected with HHV-6, as indicated by serologic testing, and approximately 2 percent of pregnant women shed low levels of virus in genital secretions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/62\">",
"     62",
"    </a>",
"    ]. In addition, HHV-6 DNA has been detected in 41 to 44 percent of samples during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/63\">",
"     63",
"    </a>",
"    ] but only 1 percent of cord blood samples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study cited above of infants and young children presenting with an acute febrile syndrome, HHV-6 DNA was detected in 10 percent of infants less than one month of age, a finding that is consistent with perinatal transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/37\">",
"     37",
"    </a>",
"    ]. Intrauterine transmission has also been proposed in selected cases in which spontaneous abortion, fetal hydrops, and fulminant neonatal hepatitis were associated with HHV-6 infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/65-67\">",
"     65-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The issue of congenital HHV-6 infection was addressed in a prospective study of 5638 children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/64\">",
"     64",
"    </a>",
"    ]. Congenital HHV-6 infections occurred in 1 percent of births, similar to the rate for cytomegalovirus infection and to the rate of isolation of HHV-6 in cord blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. All of the children with congenital infection were asymptomatic. In contrast, postnatal infections were associated with acute febrile illness, which has also been noted by others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40167/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/31/1522?source=see_link\">",
"       \"Patient information: Roseola (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1078564792\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Human herpesvirus 6 (HHV-6) is a member of the herpesviridae family. Its genetic and biologic similarities to human cytomegalovirus (CMV) have prompted its classification in the beta herpesvirus subfamily (genus Roseolovirus, along with human herpesvirus 7 [HHV-7]). As with other herpes viruses, mature HHV-6 virions are double-stranded DNA viruses, approximately 200 nm in diameter and are composed of four main structural elements: an electron-dense core, a capsid with icosahedral symmetry, a tegument, and an outer envelope. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Virology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two variants of HHV-6, HHV-6A and HHV-6B, differ in epidemiology, growth properties, nucleotide sequences, antigenic properties, and restriction endonuclease profiles. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Virology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HHV-6 replicates most efficiently in vitro in activated primary T cells as well as in continuous T cell lines. However, the virus can also replicate with varying efficiency in a wide array of host cell types including",
"      <span class=\"nowrap\">",
"       monocytes/macrophages,",
"      </span>",
"      natural killer cells, astrocytes, megakaryocytes, and glial cell lineages. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cell tropism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CD46, an immunomodulatory protein that is also called membrane cofactor protein, is a cellular receptor for HHV-6A and HHV-6B. HHV-6 integrates into the human genome; seven different chromosomal sites of integration have been identified. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Viral replication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CD4+ T cells constitute the major population of cells permissive to HHV-6 replication even though HHV-6 does not bind directly to the CD4 molecule. Once HHV-6 enters a permissive host cell, viral replication occurs relatively slowly. Within 24 hours after infection, the rate of cellular protein synthesis is high; by 65 hours after infection, host cell DNA synthesis is shut off and viral DNA synthesis is underway. Cytopathic effects can be seen within three to five days after infection. The net effect is a significant impairment in immune function. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Effect on the immune system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HHV-6 replication genes encode a number of viral proteins including U38, a viral DNA polymerase; U27, a polymerase",
"      <span class=\"nowrap\">",
"       accessory/processivity",
"      </span>",
"      protein; U41, a single-stranded DNA binding protein; and U43, U74, U77, which are three helicase-primase proteins. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Viral genes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HHV-6 seroprevalence rates vary from 20 percent among pregnant women in Morocco to 100 percent among asymptomatic Chinese adults. In industrialized nations such as the United States and Japan, rates of seroprevalence range from 72 to 95 percent. HHV-6 is frequently acquired by an early age. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The vast majority of isolates from otherwise healthy children or adults belong to subtype B. In contrast, both subtypes A and B have been recovered from peripheral blood mononuclear cells of patients who are immunocompromised or chronically ill. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Distribution of virus variants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although there are few data regarding the incubation period of HHV-6 infection, it is thought to be approximately 9 days (range 5 to 15 days). The most common route of HHV-6 transmission appears to be transfer via saliva from mother to infant. Perinatal transmission is also possible. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Incubation period and transmission'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/1\">",
"      Salahuddin SZ, Ablashi DV, Markham PD, et al. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science 1986; 234:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/2\">",
"      Ablashi DV, Salahuddin SZ, Josephs SF, et al. HBLV (or HHV-6) in human cell lines. Nature 1987; 329:207.",
"     </a>",
"    </li>",
"    <li>",
"     Pellett PE, Black JB. Human herpesvirus 6. In: Fields Virology, 3rd edition, Fields BN, Knipe DM, Howley PM (Eds), Lippincott-Raven, 1996. p.2587.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/4\">",
"      Ablashi DV, Balachandran N, Josephs SF, et al. Genomic polymorphism, growth properties, and immunologic variations in human herpesvirus-6 isolates. Virology 1991; 184:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/5\">",
"      Aubin JT, Agut H, Collandre H, et al. Antigenic and genetic differentiation of the two putative types of human herpes virus 6. J Virol Methods 1993; 41:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/6\">",
"      Dewhurst S, Chandran B, McIntyre K, et al. Phenotypic and genetic polymorphisms among human herpesvirus-6 isolates from North American infants. Virology 1992; 190:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/7\">",
"      Achour A, Malet I, Le Gal F, et al. Variability of gB and gH genes of human herpesvirus-6 among clinical specimens. J Med Virol 2008; 80:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/8\">",
"      Cermelli C, Concari M, Carubbi F, et al. Growth of human herpesvirus 6 in HEPG2 cells. Virus Res 1996; 45:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/9\">",
"      Chen M, Popescu N, Woodworth C, et al. Human herpesvirus 6 infects cervical epithelial cells and transactivates human papillomavirus gene expression. J Virol 1994; 68:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/10\">",
"      He J, McCarthy M, Zhou Y, et al. Infection of primary human fetal astrocytes by human herpesvirus 6. J Virol 1996; 70:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/11\">",
"      Luka J, Okano M, Thiele G. Isolation of human herpesvirus-6 from clinical specimens using human fibroblast cultures. J Clin Lab Anal 1990; 4:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/12\">",
"      Levine PH, Jahan N, Murari P, et al. Detection of human herpesvirus 6 in tissues involved by sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). J Infect Dis 1992; 166:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/13\">",
"      Cone RW, Huang ML, Ashley R, Corey L. Human herpesvirus 6 DNA in peripheral blood cells and saliva from immunocompetent individuals. J Clin Microbiol 1993; 31:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/14\">",
"      Kondo K, Kondo T, Okuno T, et al. Latent human herpesvirus 6 infection of human monocytes/macrophages. J Gen Virol 1991; 72 ( Pt 6):1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/15\">",
"      Okuno T, Higashi K, Shiraki K, et al. Human herpesvirus 6 infection in renal transplantation. Transplantation 1990; 49:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/16\">",
"      Krueger GR, Wassermann K, De Clerck LS, et al. Latent herpesvirus-6 in salivary and bronchial glands. Lancet 1990; 336:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/17\">",
"      Challoner PB, Smith KT, Parker JD, et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci U S A 1995; 92:7440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/18\">",
"      Luppi M, Barozzi P, Maiorana A, et al. Human herpesvirus 6 infection in normal human brain tissue. J Infect Dis 1994; 169:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/19\">",
"      Crawford JR, Santi MR, Thorarinsdottir HK, et al. Detection of human herpesvirus-6 variants in pediatric brain tumors: association of viral antigen in low grade gliomas. J Clin Virol 2009; 46:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/20\">",
"      Crawford JR, Santi MR, Cornelison R, et al. Detection of human herpesvirus-6 in adult central nervous system tumors: predominance of early and late viral antigens in glial tumors. J Neurooncol 2009; 95:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/21\">",
"      Kondo K, Kondo T, Shimada K, et al. Strong interaction between human herpesvirus 6 and peripheral blood monocytes/macrophages during acute infection. J Med Virol 2002; 67:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/22\">",
"      Andre-Garnier E, Milpied N, Boutolleau D, et al. Reactivation of human herpesvirus 6 during ex vivo expansion of circulating CD34+ haematopoietic stem cells. J Gen Virol 2004; 85:3333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/23\">",
"      Santoro F, Kennedy PE, Locatelli G, et al. CD46 is a cellular receptor for human herpesvirus 6. Cell 1999; 99:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/24\">",
"      Mori Y, Yang X, Akkapaiboon P, et al. Human herpesvirus 6 variant A glycoprotein H-glycoprotein L-glycoprotein Q complex associates with human CD46. J Virol 2003; 77:4992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/25\">",
"      Smith A, Santoro F, Di Lullo G, et al. Selective suppression of IL-12 production by human herpesvirus 6. Blood 2003; 102:2877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/26\">",
"      Karp CL, Wysocka M, Wahl LM, et al. Mechanism of suppression of cell-mediated immunity by measles virus. Science 1996; 273:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/27\">",
"      Nacheva EP, Ward KN, Brazma D, et al. Human herpesvirus 6 integrates within telomeric regions as evidenced by five different chromosomal sites. J Med Virol 2008; 80:1952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/28\">",
"      Mori Y, Koike M, Moriishi E, et al. Human herpesvirus-6 induces MVB formation, and virus egress occurs by an exosomal release pathway. Traffic 2008; 9:1728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/29\">",
"      Lusso P, Gallo RC, DeRocco SE, Markham PD. CD4 is not the membrane receptor for HHV-6. Lancet 1989; 1:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/30\">",
"      Di Luca D, Katsafanas G, Schirmer EC, et al. The replication of viral and cellular DNA in human herpesvirus 6-infected cells. Virology 1990; 175:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/31\">",
"      Lusso P, Malnati M, De Maria A, et al. Productive infection of CD4+ and CD8+ mature human T cell populations and clones by human herpesvirus 6. Transcriptional down-regulation of CD3. J Immunol 1991; 147:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/32\">",
"      Singh N. Interactions between viruses in transplant recipients. Clin Infect Dis 2005; 40:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/33\">",
"      Gupta S, Agrawal S, Gollapudi S. Differential effect of human herpesvirus 6A on cell division and apoptosis among naive and central and effector memory CD4+ and CD8+ T-cell subsets. J Virol 2009; 83:5442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/34\">",
"      Takemoto M, Imasawa T, Yamanishi K, Mori Y. Role of dendritic cells infected with human herpesvirus 6 in virus transmission to CD4(+) T cells. Virology 2009; 385:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/35\">",
"      Tai AK, Luka J, Ablashi D, Huber BT. HHV-6A infection induces expression of HERV-K18-encoded superantigen. J Clin Virol 2009; 46:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/36\">",
"      Flamand L, Stefanescu I, Menezes J. Human herpesvirus-6 enhances natural killer cell cytotoxicity via IL-15. J Clin Invest 1996; 97:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/37\">",
"      Hall CB, Long CE, Schnabel KC, et al. Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. N Engl J Med 1994; 331:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/38\">",
"      Gompels UA, Nicholas J, Lawrence G, et al. The DNA sequence of human herpesvirus-6: structure, coding content, and genome evolution. Virology 1995; 209:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/39\">",
"      Lindquester GJ, Inoue N, Allen RD, et al. Restriction endonuclease mapping and molecular cloning of the human herpesvirus 6 variant B strain Z29 genome. Arch Virol 1996; 141:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/40\">",
"      Pfeiffer B, Berneman ZN, Neipel F, et al. Identification and mapping of the gene encoding the glycoprotein complex gp82-gp105 of human herpesvirus 6 and mapping of the neutralizing epitope recognized by monoclonal antibodies. J Virol 1993; 67:4611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/41\">",
"      Isegawa Y, Ping Z, Nakano K, et al. Human herpesvirus 6 open reading frame U12 encodes a functional beta-chemokine receptor. J Virol 1998; 72:6104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/42\">",
"      Milne RS, Mattick C, Nicholson L, et al. RANTES binding and down-regulation by a novel human herpesvirus-6 beta chemokine receptor. J Immunol 2000; 164:2396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/43\">",
"      Horvat RT, Wood C, Balachandran N. Transactivation of human immunodeficiency virus promoter by human herpesvirus 6. J Virol 1989; 63:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/44\">",
"      Lusso P, Ensoli B, Markham PD, et al. Productive dual infection of human CD4+ T lymphocytes by HIV-1 and HHV-6. Nature 1989; 337:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/45\">",
"      Lusso P, Malnati MS, Garzino-Demo A, et al. Infection of natural killer cells by human herpesvirus 6. Nature 1993; 362:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/46\">",
"      Ranger S, Patillaud S, Denis F, et al. Seroepidemiology of human herpesvirus-6 in pregnant women from different parts of the world. J Med Virol 1991; 34:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/47\">",
"      Levy JA, Ferro F, Greenspan D, Lennette ET. Frequent isolation of HHV-6 from saliva and high seroprevalence of the virus in the population. Lancet 1990; 335:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/48\">",
"      Okuno T, Takahashi K, Balachandra K, et al. Seroepidemiology of human herpesvirus 6 infection in normal children and adults. J Clin Microbiol 1989; 27:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/49\">",
"      Brown NA, Sumaya CV, Liu CR, et al. Fall in human herpesvirus 6 seropositivity with age. Lancet 1988; 2:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/50\">",
"      Zerr DM, Meier AS, Selke SS, et al. A population-based study of primary human herpesvirus 6 infection. N Engl J Med 2005; 352:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/51\">",
"      Dewhurst S, McIntyre K, Schnabel K, Hall CB. Human herpesvirus 6 (HHV-6) variant B accounts for the majority of symptomatic primary HHV-6 infections in a population of U.S. infants. J Clin Microbiol 1993; 31:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/52\">",
"      Kasolo FC, Mpabalwani E, Gompels UA. Infection with AIDS-related herpesviruses in human immunodeficiency virus-negative infants and endemic childhood Kaposi's sarcoma in Africa. J Gen Virol 1997; 78 ( Pt 4):847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/53\">",
"      Knox KK, Carrigan DR. Active HHV-6 infection in the lymph nodes of HIV-infected patients: in vitro evidence that HHV-6 can break HIV latency. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/54\">",
"      Hall CB, Caserta MT, Schnabel KC, et al. Persistence of human herpesvirus 6 according to site and variant: possible greater neurotropism of variant A. Clin Infect Dis 1998; 26:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/55\">",
"      De Bolle L, Van Loon J, De Clercq E, Naesens L. Quantitative analysis of human herpesvirus 6 cell tropism. J Med Virol 2005; 75:76.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Human herpesvirus 6 (including roseola) and. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.414.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/57\">",
"      Hall, CB, Caserta, MT. Exanthem subitum (Roseola infantum). Herpes 1999; 6:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/58\">",
"      Wyatt LS, Frenkel N. Human herpesvirus 7 is a constitutive inhabitant of adult human saliva. J Virol 1992; 66:3206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/59\">",
"      Di Luca D, Mirandola P, Ravaioli T, et al. Human herpesviruses 6 and 7 in salivary glands and shedding in saliva of healthy and human immunodeficiency virus positive individuals. J Med Virol 1995; 45:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/60\">",
"      Pereira CM, Gasparetto PF, Corr&ecirc;a ME, et al. Human herpesvirus 6 in oral fluids from healthy individuals. Arch Oral Biol 2004; 49:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/61\">",
"      Roush KS, Domiati-Saad RK, Margraf LR, et al. Prevalence and cellular reservoir of latent human herpesvirus 6 in tonsillar lymphoid tissue. Am J Clin Pathol 2001; 116:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/62\">",
"      Baillargeon J, Piper J, Leach CT. Epidemiology of human herpesvirus 6 (HHV-6) infection in pregnant and nonpregnant women. J Clin Virol 2000; 16:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/63\">",
"      Dahl H, Fjaertoft G, Norsted T, et al. Reactivation of human herpesvirus 6 during pregnancy. J Infect Dis 1999; 180:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/64\">",
"      Hall CB, Caserta MT, Schnabel KC, et al. Congenital infections with human herpesvirus 6 (HHV6) and human herpesvirus 7 (HHV7). J Pediatr 2004; 145:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/65\">",
"      Aubin JT, Poirel L, Agut H, et al. Intrauterine transmission of human herpesvirus 6. Lancet 1992; 340:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/66\">",
"      Ashshi AM, Cooper RJ, Klapper PE, et al. Detection of human herpes virus 6 DNA in fetal hydrops. Lancet 2000; 355:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40167/abstract/67\">",
"      Asano Y, Yoshikawa T, Suga S, et al. Fatal fulminant hepatitis in an infant with human herpesvirus-6 infection. Lancet 1990; 335:862.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8302 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-CE19846B1C-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_14_40167=[""].join("\n");
var outline_f39_14_40167=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1078564792\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VIROLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cell tropism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Viral replication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Effect on the immune system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Viral genes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Distribution of virus variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Incubation period and transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1078564792\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8302\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8302|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/45/27358\" title=\"figure 1\">",
"      HHV 6 infants young children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/1/10265?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of human herpesvirus-6 infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31577?source=related_link\">",
"      Human herpesvirus 6 infection in children: Clinical manifestations; diagnosis; and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/40/30346?source=related_link\">",
"      Human herpesvirus 6 infection in hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/54/29544?source=related_link\">",
"      Pathogenesis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/31/1522?source=related_link\">",
"      Patient information: Roseola (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_14_40168="Autoimmune pancreatitis";
var content_f39_14_40168=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Autoimmune pancreatitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/14/40168/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/14/40168/contributors\">",
"     Norton J Greenberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/14/40168/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/14/40168/contributors\">",
"     David C Whitcomb, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/14/40168/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/14/40168/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/14/40168/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune pancreatitis (AIP) is an infrequently recognized disorder of presumed autoimmune etiology that is associated with characteristic clinical, histologic, and morphologic findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/1\">",
"     1",
"    </a>",
"    ]. Most of the early literature pertaining to AIP came from Japan, where the incidence may be increasing, perhaps due to increased recognition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/2\">",
"     2",
"    </a>",
"    ]. However, it has been described in several countries in Europe as well as the United States and Korea, suggesting that it is a worldwide entity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AIP can occur as a primary pancreatic disorder or in association with other disorders of presumed autoimmune etiology, including IgG4 cholangitis, salivary gland disorders, mediastinal fibrosis, retroperitoneal fibrosis, tubulointerstitial disease, and inflammatory bowel disease (",
"    <a class=\"graphic graphic_table graphicRef81268 \" href=\"mobipreview.htm?35/43/36539\">",
"     table 1",
"    </a>",
"    ). Several publications have indicated that AIP is actually an IgG4 systemic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/55/13178?source=see_link\">",
"     \"Overview of IgG4-related disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune pancreatitis (AIP) has been referred to by a variety of names including sclerosing pancreatitis, tumefactive pancreatitis, and nonalcoholic destructive pancreatitis, depending in part upon the specific pathologic findings and the presence of extrapancreatic manifestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. However, it is generally believed that the pathologic heterogeneity may reflect different stages or manifestations of the same disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with AIP, IgG4 positive plasma cells are considered a marker for the disease and can be detected in the pancreas and a variety of other tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. In addition, serum IgG4 levels are elevated to more than two times the upper limit of normal in most patients. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Other manifestations'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H11\">",
"     'Serologic testing for IgG4'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although earlier reports linked autoimmune pancreatitis to primary sclerosing cholangitis (PSC), it is now recognized that intrahepatic and extrahepatic biliary tract abnormalities with strictures are most often due to IgG4-associated cholangitis. Nine to 36 percent of patients with findings indicative of PSC have been found to have elevated IgG4 levels compared with 1 percent in other chronic liver diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H61253267\">",
"     'Distinction of IAC from PSC'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of clinical features have been described that may reflect different stages of autoimmune pancreatitis (",
"    <a class=\"graphic graphic_table graphicRef81268 \" href=\"mobipreview.htm?35/43/36539\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58707 \" href=\"mobipreview.htm?3/35/3643\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/14-22\">",
"     14-22",
"    </a>",
"    ]. The manifestations occur in the pancreas, biliary tract, and other organs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pancreatic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of manifestations related to the pancreas and biliary tract have been described in patients with autoimmune pancreatitis (AIP):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A pancreatic mass that can be confused with pancreatic carcinoma or lymphoma. A pancreatic mass, enlargement, or prominence on imaging was present in 85 percent of patients in an early report of 26 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mild abdominal pain with or without attacks of acute pancreatitis and chronic pancreatitis. Recurrent pancreatitis is common (25 percent in a series of 87 patients), and occurs more frequently in patients with focal compared with diffuse pancreatitis (33 versus 13 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/23\">",
"       23",
"      </a>",
"      ]. Although recurrence is common, AIP is not a frequent cause of idiopathic recurrent pancreatitis, at least in western countries [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pancreatic duct strictures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/15,22,25\">",
"       15,22,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Peripancreatic vascular complications are rare, although in the series cited above they were present in 23 percent of patients with AIP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Biliary tract manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common presentation of AIP is obstructive jaundice. The term IgG4-associated cholangitis (IAC) has been proposed for the biliary tract manifestations of AIP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/15,26\">",
"     15,26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Terminology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In a series of 53 patients with IAC, biliary strictures were associated with AIP in 92 percent and confined to the proximal",
"    <span class=\"nowrap\">",
"     extrahepatic/intrahepatic",
"    </span>",
"    ducts in 49 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/15\">",
"     15",
"    </a>",
"    ]. Patients with IAC were more frequently older men who presented with obstructive jaundice (77 percent) and increased serum IgG4 levels (74 percent).",
"   </p>",
"   <p>",
"    Another report evaluated 26 patients with AIP in whom",
"    <span class=\"nowrap\">",
"     extrapancreatic/intrahepatic",
"    </span>",
"    biliary strictures were present in nine patients (35 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/16\">",
"     16",
"    </a>",
"    ]. Autoimmune sclerosing cholangitis has also been described.",
"   </p>",
"   <p>",
"    An obstructive pattern of liver function tests (ie, a disproportionately elevated serum alkaline phosphatase and minimally elevated serum aminotransferases) is commonly seen in patients with biliary tract involvement. These features can also be seen in patients with pancreatic cancer or cholangiocarcinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other organs can be involved in patients with AIP. These include the salivary glands (Sj&ouml;gren's syndrome), bile duct strictures, lung nodules, autoimmune thyroiditis, and kidney (interstitial nephritis with an IgG4-positive plasma cell infiltrate and IgG4 deposits in the tubular basement membrane) (",
"    <a class=\"graphic graphic_table graphicRef81268 \" href=\"mobipreview.htm?35/43/36539\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1731730186\">",
"    <span class=\"h2\">",
"     Distinct clinical profiles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune pancreatitis is now classified into two types. In type 1 AIP, the pancreas is involved as one part of a systemic IgG4-positive disease and meets the HISORt criteria. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/55/13178?source=see_link\">",
"     \"Overview of IgG4-related disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Type 2 AIP is characterized by histologically confirmed idiopathic duct centric pancreatitis often with granulocytic lesions, but without IgG4-positive cells and without systemic involvement. In a study of 97 patients with AIP, patients with type 1 AIP were found to have a high relapse rate compared to patients with type 2 AIP who do not experience relapse (49 versus 0 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, at presentation patients with type 1 AIP were older, had a greater prevalence of IgG4 elevations, and were more likely to have biliary tract disease, retroperitoneal, renal, or salivary gland disease than patients with type 2 AIP. Type 2 AIP is more frequently associated with inflammatory bowel disease than type 1.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune pancreatitis (AIP) should be considered in the differential diagnosis of patients presenting with the varied symptoms referable to the pancreas and biliary tract described above, particularly in those with other autoimmune conditions. Correct diagnosis can help avert the consequences of progressive disease and unnecessary surgery. An important part of the differential diagnosis is distinguishing AIP from pancreatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/27,30\">",
"     27,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A pancreatic biopsy is usually required to establish the diagnosis, and is one component of the Mayo Clinic HISORt diagnostic criteria (see below). The presence of immunostaining for IgG4 in plasma cell infiltrates in both the pancreas and extrapancreatic tissues provides support for the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/27,31-33\">",
"     27,31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnostic criteria have been proposed by several groups including the Japanese Pancreas Society, an expert group from Korea, and the Mayo Clinic in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/16\">",
"     16",
"    </a>",
"    ]. In one series of patients with established AIP, about 85 percent of patients fulfilled the diagnostic criteria of at least one of the groups, suggesting that none of the sets of diagnostic criteria is 100 percent sensitive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnostic criteria proposed by the Mayo Clinic (the \"HISORt\" criteria) are most commonly used in the United States and include the presence of one or more of the following (",
"    <a class=\"graphic graphic_table graphicRef74331 \" href=\"mobipreview.htm?26/37/27227\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/27,34\">",
"     27,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diagnostic",
"      <strong>",
"       H",
"      </strong>",
"      istology",
"     </li>",
"     <li>",
"      Characteristic",
"      <strong>",
"       I",
"      </strong>",
"      maging on computed tomography",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pancreatography",
"     </li>",
"     <li>",
"      Elevated serum IgG4 levels on",
"      <strong>",
"       S",
"      </strong>",
"      erologic testing",
"     </li>",
"     <li>",
"      <strong>",
"       O",
"      </strong>",
"      ther organ involvement (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Other manifestations'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      <strong>",
"       R",
"      </strong>",
"      esponse of pancreatic and extrapancreatic manifestations to glucocorticoid",
"      <strong>",
"       t",
"      </strong>",
"      herapy (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Glucocorticoids'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H15\">",
"       'Biliary strictures'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;A report from the Mayo Clinic described the following findings as being highly suggestive or diagnostic of AIP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A lymphoplasmacytic sclerosing pancreatitis OR more than 10 IgG4-positive cells with at least two of the following: periductal lymphoplasmacytic infiltrate, obliterative phlebitis, and acinar fibrosis (type 1) (",
"      <a class=\"graphic graphic_picture graphicRef64636 \" href=\"mobipreview.htm?30/16/30976\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef53366 graphicRef74906 graphicRef63135 graphicRef63668 graphicRef55993 graphicRef74906 graphicRef63135 graphicRef71710 \" href=\"mobipreview.htm?43/45/44762\">",
"       picture 2A-B, 2B-C, 2C-F",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Idiopathic duct centric pancreatitis OR a granulocytic epithelial lesion in the pancreatic duct with minimal IgG4-positive cells in the pancreatic parenchyma (type 2).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Endoscopic ultrasound (EUS)-guided fine-needle aspiration (FNA) may be an option for obtaining histologic specimens from the pancreas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. In a study of 44 patients with AIP, 19 (43 percent) had findings on histologic examination of samples obtained during EUS FNA that suggested AIP (14 samples showed lymphoplasmacytic sclerosing pancreatitis, two samples with IgG4-positive plasma cells, and three samples with both) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/35\">",
"     35",
"    </a>",
"    ]. Despite the low sensitivity (43 percent), EUS FNA may still have a role since, if positive, it may allow patients to avoid surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;AIP is usually first suggested by an imaging test such as contrast enhanced computed tomography (CT) or magnetic resonance imaging (MRI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/25,27,30,37-40\">",
"     25,27,30,37-40",
"    </a>",
"    ]. The main findings that are diagnostic or highly suggestive of AIP are a diffusely enlarged pancreas with featureless borders and delayed enhancement with or without a capsule-like rim [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/27\">",
"     27",
"    </a>",
"    ]. By contrast, findings that are highly suggestive or diagnostic of pancreatic cancer include a low density mass, dilatation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cutoff of the pancreatic duct, and distal pancreatic atrophy.",
"   </p>",
"   <p>",
"    Endoscopic retrograde cholangiopancreatography (ERCP) or magnetic resonance cholangiopancreatography (MRCP) may reveal a narrowed main and dorsal pancreatic duct; diffuse, irregular narrowing of the pancreatic duct (beaded appearance), or a focal stricture of the pancreatic duct, proximal or distal common bile duct; or irregular narrowing of the intrahepatic ducts (",
"    <a class=\"graphic graphic_figure graphicRef53448 \" href=\"mobipreview.htm?43/26/44451\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A stricture in the common bile duct (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52843 \" href=\"mobipreview.htm?24/62/25568\">",
"     image 1",
"    </a>",
"    ) or the finding of a lesion in the head of the pancreas often prompts consideration of malignancy. Thus, it may not be possible to distinguish AIP from pancreatic cancer based solely upon imaging tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endoscopic ultrasonography and transabdominal ultrasonography have also been evaluated in patients with AIP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/43-45\">",
"     43-45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Serologic testing for IgG4",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic testing for IgG4 is an important component of evaluating a patient suspected of having autoimmune pancreatitis. IgG4 accounts for only 5 to 6 percent of the total serum IgG in healthy subjects and is typically less than 140",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    A serum concentration of IgG4 that is &ge;2 times the upper limit of normal is highly suggestive of AIP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/27\">",
"     27",
"    </a>",
"    ], but may not rule out pancreatic cancer. This cutoff was chosen because values less than twice the upper limit of normal (serum IgG4 &le;280",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    are seen in up to 10 percent of individuals with pancreatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The value of serum IgG4 levels was demonstrated in a study that included 20 patients with AIP (based upon clinical features and response to glucocorticoids), 20 age- and sex&ndash;matched healthy controls, and 154 patients with pancreatic cancer, ordinary chronic pancreatitis, primary biliary cirrhosis, primary sclerosing cholangitis, or Sj&ouml;gren's syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/47\">",
"     47",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The median serum IgG4 concentration was much higher in patients with AIP compared with healthy controls (663 versus 51",
"      <span class=\"nowrap\">",
"       mg/dL).",
"      </span>",
"      Among patients with AIP, serum IgG4 declined during treatment with glucocorticoids. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Glucocorticoids'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The serum IgG4 concentration in the patients with other diseases was similar to those in healthy subjects, with no values above 135",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"      However, in other reports some patients with primary sclerosing cholangitis (9 percent in a series of 127 patients) have had elevated serum IgG4 levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/49\">",
"       49",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22521?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical manifestations and diagnosis of primary sclerosing cholangitis\", section on 'Laboratory tests'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Using a cutoff of 135",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      the sensitivity and specificity of serum IgG4 for distinguishing AIP from pancreatic cancer were 95 and 97 percent, respectively, although the sensitivity and specificity were lower in subsequent studies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The value of serum IgG4 in distinguishing AIP from pancreatic cancer was also demonstrated in a later and larger series from the Mayo Clinic that included 45 patients with AIP and 135 with pancreatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/46\">",
"     46",
"    </a>",
"    ]. At serum IgG4 concentrations of more than 140",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and more than 280",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    the sensitivity for the diagnosis of AIP fell from 76 to 53 percent, while the specificity increased from 93 to 99 percent. Only 1 percent of the patients with pancreatic cancer had serum IgG4 levels above 280",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    while elevated serum CA 19-9 concentrations were much more common with pancreatic cancer (71 versus 9 percent). Among 268 patients with other pancreatic diseases, only two of the 58 patients with acute pancreatitis had a serum IgG4 above 280",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.4 percent of patients with acute pancreatitis and 0.7 percent of all patients with other pancreatic diseases).",
"   </p>",
"   <p>",
"    In another study, seven percent of patients with pancreatic cancer had serum IgG4 levels above 135",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/48\">",
"     48",
"    </a>",
"    ]. These authors suggested that in patients with pancreatic mass lesions and suspicion of cancer, an IgG4 level measuring between 135 and 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    should be interpreted cautiously and not accepted as diagnostic of autoimmune pancreatitis without further evaluation, especially since pancreatic cancer is much more common than autoimmune pancreatitis.",
"   </p>",
"   <p>",
"    The sensitivity values in the Mayo Clinic study demonstrate that many patients with AIP do not have serum IgG4 levels above 280",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/46\">",
"     46",
"    </a>",
"    ]. This may represent a subtype of AIP with a younger age of onset, equal sex distribution, and more often associated with inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/50\">",
"     50",
"    </a>",
"    ]. In addition to pancreatic cancer, serum IgG4 values above normal but &le;280",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    have been described in a number of disorders that do not involve the pancreas, including atopic dermatitis, asthma, some parasitic diseases, pemphigus vulgaris, and pemphigus foliaceus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. The elevation in serum IgG4 in these patients is usually accompanied by an elevation in serum IgE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Anti-PBP peptide antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-plasminogen-binding protein (PBP) peptide antibodies may help diagnose patients with AIP. One study that included an initial and a validation cohort detected anti-PBP peptide antibodies in 33 of 35 patients (94 percent) with autoimmune pancreatitis and in no healthy controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/54\">",
"     54",
"    </a>",
"    ]. However, these antibodies were also present in 5 of 110 patients (5 percent) with pancreatic cancer. As a result, it cannot be used to distinguish between these two diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1684448\">",
"    <span class=\"h2\">",
"     Other antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other antibodies that may be elevated in patients with AIP include antibodies to carbonic anhydrase II antigens (positive in 30 to 59 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/55\">",
"     55",
"    </a>",
"    ] and lactoferrin (positive in 50 to 76 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/56\">",
"     56",
"    </a>",
"    ]. Additional antibodies that have been associated with AIP, but that have not been consistently positive, include rheumatoid factor, perinuclear antineutrophil cytoplasmic antibody, antinuclear antibody, antimitochondrial antibody, anti-smooth muscle antibody, and antithyroglobulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/57-59\">",
"     57-59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61253267\">",
"    <span class=\"h2\">",
"     Distinction of IAC from PSC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain cholangiographic features may help distinguish biliary involvement of AIP (IgG4-associated cholangitis; IAC) from primary sclerosing cholangitis (PSC), which has similar clinical features and, in some patients, elevations in serum IgG4 (though less pronounced than those seen in IAC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Serologic testing for IgG4'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In one report, cholangiograms from patients with PSC were more likely to show band-like strictures, a beaded or pruned-tree appearance, or diverticulum-like formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/60\">",
"     60",
"    </a>",
"    ]. By contrast, segmental strictures, long strictures with prestenotic dilation, and strictures of the distal common bile duct were more common in IAC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another distinguishing feature is that IAC but not PSC typically responds to glucocorticoid therapy. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Glucocorticoids'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/8/41097?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of primary sclerosing cholangitis\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of autoimmune pancreatitis (AIP) is based upon observational data, since there have been no randomized controlled trials. Comparison among studies can be difficult because of heterogeneous patient groups, use of different diagnostic criteria, and definitions of response. Despite these limitations, most patients respond to glucocorticoid therapy, but the relapse rate is significant. Pooling the data from three studies of patients with AIP or IgG4-associated cholangitis (IAC), the response rate to glucocorticoids was 87 percent (67 of 77 patients), with a relapse rate of 62 percent (34 of 55 patients) (",
"    <a class=\"graphic graphic_table graphicRef83587 \" href=\"mobipreview.htm?17/35/17980\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/15,16,26\">",
"     15,16,26",
"    </a>",
"    ]. However, many patients who relapsed responded to treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (23 of 50 patients, 46 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;AIP often responds to glucocorticoids, both improving clinical manifestations and potentially preventing complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/30,62-64\">",
"     30,62-64",
"    </a>",
"    ]. In most reports, one-half to two-thirds of patients responded to glucocorticoids, but about 25 percent required a second course of treatment, while a smaller proportion needed continuous treatment.",
"   </p>",
"   <p>",
"    The time to response is variable, usually occurring within two weeks to four months. Patients are typically followed with serum IgG4 levels, liver biochemical tests, and by CT scan while on therapy. As mentioned above, the response to glucocorticoid therapy is one of the HISORt criteria for the diagnosis of AIP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Studies of steroids in AIP have shown the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An illustrative report included 42 patients with AIP, 19 of whom were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/62\">",
"       62",
"      </a>",
"      ]. The patients were treated with prednisolone (30 to 40",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for two to four weeks; the dose was tapered by 5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      every two to four weeks until reaching 5",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      The maintenance dose was 2.5 to 5",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      The average observation period was 25 months (up to seven years). Imaging studies (ultrasonography, computed tomography, or magnetic resonance imaging) were performed every six months, and biochemical parameters were measured every three to six months.",
"      <br/>",
"      <br/>",
"      Unfavorable events (sclerosing cholangitis, distal bile duct stenosis, and retroperitoneal fibrosis) were significantly less common in the patients treated with prednisolone (32 versus 70 percent). This finding supports the recommendation that AIP patients, especially those with obstructive jaundice and bile duct strictures, should be treated and maintained on glucocorticoids.",
"     </li>",
"     <li>",
"      Another study evaluated the utility of a two-week trial of glucocorticoid therapy in 22 patients who had atypical imaging findings for AIP and did not meet the classic imaging criteria for pancreatic cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/63\">",
"       63",
"      </a>",
"      ]. All patients were treated with oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      (0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day). At two weeks, glucocorticoid responsiveness was defined as a marked improvement in narrowing of the main pancreatic duct and a reduction in the pancreatic mass. All 15 patients who responded were diagnosed as having AIP, while the presence of pancreatic cancer was confirmed in all seven patients who did not respond.",
"     </li>",
"     <li>",
"      A third report described 44 patients with either type 1 AIP (64 percent of the patients) or type 2 AIP (36 percent of the patients) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/65\">",
"       65",
"      </a>",
"      ]. Steroids were effective in all treated patients but relapse occurred in 12 patients (27 percent) after a median delay of six months (range 1 to 70 months). High serum IgG4 levels at the time of diagnosis and other organ involvement were associated with relapse. Exocrine and endocrine insufficiencies were present in 34 and 39 percent of the patients, respectively. Steroids, with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      treatment, did not prevent pancreatic exocrine insufficiency. Type 2 AIP was more frequently associated with inflammatory bowel disease than type 1 AIP (31 and 3 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Radiologic features that predict a response to glucocorticoids have been identified but their predictive accuracy remains uncertain. In one report, for example, CT findings of diffuse swelling and a halo (a hypoattenuating rim surrounding the pancreas) were predictive of a favorable response to glucocorticoids, while predictors of a suboptimal response were ductal strictures (2 of 13 suboptimal) and a focal mass-like swelling that persisted after resolution of diffuse changes (7 of 13) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/66\">",
"     66",
"    </a>",
"    ]. It was proposed that the predictors of a favorable response represented an early inflammatory phase, while predictors of a suboptimal response represented a late stage with a predominance of fibrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Biliary strictures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to glucocorticoids in patients who have biliary strictures is more variable than the response in patients with pancreatitis. In some reports, strictures responded to glucocorticoids, while in others they did not respond, had an incomplete response, or required maintenance therapy with glucocorticoids",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    immunomodulatory drugs to prevent relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/15,26,34,67,68\">",
"     15,26,34,67,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An illustrative series included 53 patients with IgG4-associated cholangitis (IAC), 30 of whom were treated initially with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for four weeks followed by a taper of 5 mg per week for a total of 11 weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/15\">",
"     15",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Biliary strictures were confined to the intrahepatic duct in 51 percent of IAC patients.",
"     </li>",
"     <li>",
"      The proximal",
"      <span class=\"nowrap\">",
"       extrahepatic/intrahepatic",
"      </span>",
"      ducts were involved in 49 percent of IAC patients.",
"     </li>",
"     <li>",
"      An initial response to glucocorticoids was seen in 29 patients (97 percent), but only 18 (60 percent) had resolution of strictures and normalization of liver biochemical tests.",
"     </li>",
"     <li>",
"      Relapse was seen in 71 percent of patients with a proximal stricture, less than six months after the glucocorticoid was tapered; the presence of intrahepatic or proximal extrahepatic strictures was predictive of relapse in these patients. Among 15 patients retreated with glucocorticoids, eight (44 percent) relapsed when they were tapered. Seven patients who had at least one relapse were treated with immunomodulatory drugs. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Immunomodulatory drugs'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A prospective study evaluated 28 patients with AIP, 23 of whom had coexisting IAC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/26\">",
"     26",
"    </a>",
"    ]. All patients responded within six weeks to glucocorticoid therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    30",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    which was tapered by 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    every two weeks). Prednisolone was discontinued, if possible, after three to four months. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Remission was attained in 23 patients at a median of five months (range 1.5 to 17 months).",
"     </li>",
"     <li>",
"      Five patients could not be weaned because of disease flare and eight patients who attained remission relapsed. These patients were treated with an increased glucocorticoid dose and reinstitution of glucocorticoid therapy, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Immunomodulatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest that immunomodulatory drugs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    has been best studied) are effective in patients who fail steroids, relapse, or cannot be weaned for steroids. The following observations were noted in the two studies discussed in the preceding section:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Seven patients in the first study who had at least one relapse were treated with immunomodulatory drugs (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      in four,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil in two, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      in one). Three of the seven patients were maintained on glucocorticoids. All seven patients remained in remission at a median follow-up of six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 13 patients in the second study, 10 were also treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/26\">",
"       26",
"      </a>",
"      ]. Remission was achieved and maintained in seven patients with azathioprine monotherapy at a median follow-up of 14 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Successful treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , a monoclonal antibody, was reported in two patients with AIP, one who was refractory to glucocorticoids and 6-mercaptopurine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/69\">",
"     69",
"    </a>",
"    ], and one who relapsed while on glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/70\">",
"     70",
"    </a>",
"    ]. Further data are required before such an approach can be recommended.",
"   </p>",
"   <p>",
"    Some important questions remain unanswered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Should glucocorticoids be tapered at a slower rate than 5 mg every two weeks?",
"     </li>",
"     <li>",
"      How long should treatment be continued?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some authors have suggested an analogy with autoimmune hepatitis, in which the criterion for altering therapy is a documented sustained remission for two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40168/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40058?source=see_link&amp;anchor=H63171402#H63171402\">",
"     \"Treatment of autoimmune hepatitis\", section on 'Withdrawing therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autoimmune pancreatitis (AIP) is an infrequently recognized disorder of presumed autoimmune etiology that is associated with characteristic clinical, histologic, and morphologic findings. It has been described as a primary pancreatic disorder and also in association with other diseases of presumed autoimmune etiology. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several clinical features have been described possibly reflecting different stages of the disease or varying extrapancreatic manifestations. These include mild, acute recurrent pancreatitis, biliary and pancreatic duct strictures with a clinical presentation resembling primary sclerosing cholangitis, and a pancreatic mass that can be confused with pancreatic carcinoma or lymphoma (",
"      <a class=\"graphic graphic_table graphicRef81268 \" href=\"mobipreview.htm?35/43/36539\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AIP should be considered in the differential diagnosis of patients presenting with varied pancreatic and hepatobiliary manifestations. A pancreatic biopsy is required to establish the diagnosis, although it is also supported by elevated serum levels of IgG4, characteristic radiologic findings and response to corticosteroids. The diagnostic criteria proposed by the Mayo Clinic (the \"HISORt\" criteria) are most commonly used in the United States to establish the diagnosis (",
"      <a class=\"graphic graphic_table graphicRef74331 \" href=\"mobipreview.htm?26/37/27227\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients with AIP be treated with glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The optimal dose and duration have not been established. Our approach is to initiate treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      at a dosage of 40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for four to six weeks followed by a taper of 5",
"      <span class=\"nowrap\">",
"       mg/week.",
"      </span>",
"      Toward the end of the four- to six-week induction period, we perform repeat imaging tests (typically CT or MRI, whichever was obtained initially) to evaluate for radiologic improvement (eg, a decrease in focal mass, diffuse swelling, narrowed pancreatic duct or biliary strictures). Most patients destined to respond demonstrate clinical",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiologic improvement within the first four to six weeks. Failure to respond in this timeframe should raise the possibility of alternative diagnoses. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who relapse upon a reduction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      discontinuation of glucocorticoids can be managed with a repeat course",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      maintenance therapy aiming for the minimum glucocorticoid dose that provides a maintained response (typically in range of 10 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      daily). In our experience, an incomplete response",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      relapse is more likely in patients who have biliary strictures. We suggest using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in those with coexisting immunoglobulin G4-associated cholangitis who fail steroid weaning or relapse. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Biliary strictures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/1\">",
"      Finkelberg DL, Sahani D, Deshpande V, Brugge WR. Autoimmune pancreatitis. N Engl J Med 2006; 355:2670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/2\">",
"      Okazaki K. Autoimmune pancreatitis is increasing in Japan. Gastroenterology 2003; 125:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/3\">",
"      Kim KP, Kim MH, Lee SS, et al. Autoimmune pancreatitis: it may be a worldwide entity. Gastroenterology 2004; 126:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/4\">",
"      Kamisawa T, Egawa N, Nakajima H. Autoimmune pancreatitis is a systemic autoimmune disease. Am J Gastroenterol 2003; 98:2811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/5\">",
"      Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 2012; 366:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/6\">",
"      Garber T, Farrell TJ. Autoimmune pancreatitis: Time for a single nomenclature (abstract). Gastroenterology 2004; 126(Suppl 2):255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/7\">",
"      DiMagno EP. Autoimmune chronic pancreatitis: a plea for simplification and consistency. Clin Gastroenterol Hepatol 2003; 1:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/8\">",
"      Kamisawa T, Funata N, Hayashi Y, et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol 2003; 38:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/9\">",
"      Shinji A, Sano K, Hamano H, et al. Autoimmune pancreatitis is closely associated with gastric ulcer presenting with abundant IgG4-bearing plasma cell infiltration. Gastrointest Endosc 2004; 59:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/10\">",
"      Takeda S, Haratake J, Kasai T, et al. IgG4-associated idiopathic tubulointerstitial nephritis complicating autoimmune pancreatitis. Nephrol Dial Transplant 2004; 19:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/11\">",
"      Saeki T, Saito A, Hiura T, et al. Lymphoplasmacytic infiltration of multiple organs with immunoreactivity for IgG4: IgG4-related systemic disease. Intern Med 2006; 45:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/12\">",
"      Umemura T, Zen Y, Hamano H, et al. Immunoglobin G4-hepatopathy: association of immunoglobin G4-bearing plasma cells in liver with autoimmune pancreatitis. Hepatology 2007; 46:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/13\">",
"      Kalaitzakis E, Webster GJ. Review article: autoimmune pancreatitis - management of an emerging disease. Aliment Pharmacol Ther 2011; 33:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/14\">",
"      Hirano K, Shiratori Y, Komatsu Y, et al. Involvement of the biliary system in autoimmune pancreatitis: a follow-up study. Clin Gastroenterol Hepatol 2003; 1:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/15\">",
"      Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008; 134:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/16\">",
"      Raina A, Yadav D, Krasinskas AM, et al. Evaluation and management of autoimmune pancreatitis: experience at a large US center. Am J Gastroenterol 2009; 104:2295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/17\">",
"      Tabata M, Kitayama J, Kanemoto H, et al. Autoimmune pancreatitis presenting as a mass in the head of the pancreas: a diagnosis to differentiate from cancer. Am Surg 2003; 69:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/18\">",
"      Erkelens GW, Vleggaar FP, Lesterhuis W, et al. Sclerosing pancreato-cholangitis responsive to steroid therapy. Lancet 1999; 354:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/19\">",
"      Kojima E, Kimura K, Noda Y, et al. Autoimmune pancreatitis and multiple bile duct strictures treated effectively with steroid. J Gastroenterol 2003; 38:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/20\">",
"      Horiuchi A, Kaneko T, Yamamura N, et al. Autoimmune chronic pancreatitis simulating pancreatic lymphoma. Am J Gastroenterol 1996; 91:2607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/21\">",
"      Hamano H, Kawa S, Uehara T, et al. Immunoglobulin G4-related lymphoplasmacytic sclerosing cholangitis that mimics infiltrating hilar cholangiocarcinoma: part of a spectrum of autoimmune pancreatitis? Gastrointest Endosc 2005; 62:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/22\">",
"      Church NI, Pereira SP, Deheragoda MG, et al. Autoimmune pancreatitis: clinical and radiological features and objective response to steroid therapy in a UK series. Am J Gastroenterol 2007; 102:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/23\">",
"      Frulloni L, Scattolini C, Falconi M, et al. Autoimmune pancreatitis: differences between the focal and diffuse forms in 87 patients. Am J Gastroenterol 2009; 104:2288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/24\">",
"      Varadarajulu S, Cotton PB. Autoimmune pancreatitis: is it relevant in the west? Gastroenterology 2003; 125:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/25\">",
"      Sahani DV, Kalva SP, Farrell J, et al. Autoimmune pancreatitis: imaging features. Radiology 2004; 233:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/26\">",
"      Sandanayake NS, Church NI, Chapman MH, et al. Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol 2009; 7:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/27\">",
"      Chari ST, Takahashi N, Levy MJ, et al. A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer. Clin Gastroenterol Hepatol 2009; 7:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/28\">",
"      Cornell LD, Chicano SL, Deshpande V, et al. Pseudotumors due to IgG4 immune-complex tubulointerstitial nephritis associated with autoimmune pancreatocentric disease. Am J Surg Pathol 2007; 31:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/29\">",
"      Sah RP, Chari ST, Pannala R, et al. Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology 2010; 139:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/30\">",
"      Kamisawa T, Egawa N, Nakajima H, et al. Clinical difficulties in the differentiation of autoimmune pancreatitis and pancreatic carcinoma. Am J Gastroenterol 2003; 98:2694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/31\">",
"      Deheragoda MG, Church NI, Rodriguez-Justo M, et al. The use of immunoglobulin g4 immunostaining in diagnosing pancreatic and extrapancreatic involvement in autoimmune pancreatitis. Clin Gastroenterol Hepatol 2007; 5:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/32\">",
"      Deshpande V, Chicano S, Chiocca S, et al. Autoimmune pancreatitis: a systemic immune complex mediated disease. Am J Surg Pathol 2006; 30:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/33\">",
"      Zhang L, Notohara K, Levy MJ, et al. IgG4-positive plasma cell infiltration in the diagnosis of autoimmune pancreatitis. Mod Pathol 2007; 20:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/34\">",
"      Chari ST, Smyrk TC, Levy MJ, et al. Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. Clin Gastroenterol Hepatol 2006; 4:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/35\">",
"      Iwashita T, Yasuda I, Doi S, et al. Use of samples from endoscopic ultrasound-guided 19-gauge fine-needle aspiration in diagnosis of autoimmune pancreatitis. Clin Gastroenterol Hepatol 2012; 10:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/36\">",
"      Kanno A, Ishida K, Hamada S, et al. Diagnosis of autoimmune pancreatitis by EUS-FNA by using a 22-gauge needle based on the International Consensus Diagnostic Criteria. Gastrointest Endosc 2012; 76:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/37\">",
"      Eerens I, Vanbeckevoort D, Vansteenbergen W, Van Hoe L. Autoimmune pancreatitis associated with primary sclerosing cholangitis: MR imaging findings. Eur Radiol 2001; 11:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/38\">",
"      Irie H, Honda H, Baba S, et al. Autoimmune pancreatitis: CT and MR characteristics. AJR Am J Roentgenol 1998; 170:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/39\">",
"      Yang DH, Kim KW, Kim TK, et al. Autoimmune pancreatitis: radiologic findings in 20 patients. Abdom Imaging 2006; 31:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/40\">",
"      Nakazawa T, Ohara H, Sano H, et al. Difficulty in diagnosing autoimmune pancreatitis by imaging findings. Gastrointest Endosc 2007; 65:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/41\">",
"      Horiuchi A, Kawa S, Hamano H, et al. ERCP features in 27 patients with autoimmune pancreatitis. Gastrointest Endosc 2002; 55:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/42\">",
"      Kamisawa T, Tu Y, Egawa N, et al. Involvement of pancreatic and bile ducts in autoimmune pancreatitis. World J Gastroenterol 2006; 12:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/43\">",
"      Farrell JJ, Garber J, Sahani D, Brugge WR. EUS findings in patients with autoimmune pancreatitis. Gastrointest Endosc 2004; 60:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/44\">",
"      Hyodo N, Hyodo T. Ultrasonographic evaluation in patients with autoimmune-related pancreatitis. J Gastroenterol 2003; 38:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/45\">",
"      Numata K, Ozawa Y, Kobayashi N, et al. Contrast-enhanced sonography of autoimmune pancreatitis: comparison with pathologic findings. J Ultrasound Med 2004; 23:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/46\">",
"      Ghazale A, Chari ST, Smyrk TC, et al. Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. Am J Gastroenterol 2007; 102:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/47\">",
"      Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001; 344:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/48\">",
"      Raina A, Krasinskas AM, Greer JB, et al. Serum immunoglobulin G fraction 4 levels in pancreatic cancer: elevations not associated with autoimmune pancreatitis. Arch Pathol Lab Med 2008; 132:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/49\">",
"      Mendes FD, Jorgensen R, Keach J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 2006; 101:2070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/50\">",
"      Sugumar A, Kl&ouml;ppel G, Chari ST. Autoimmune pancreatitis: pathologic subtypes and their implications for its diagnosis. Am J Gastroenterol 2009; 104:2308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/51\">",
"      Aalberse RC, Van Milligen F, Tan KY, Stapel SO. Allergen-specific IgG4 in atopic disease. Allergy 1993; 48:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/52\">",
"      Rock B, Martins CR, Theofilopoulos AN, et al. The pathogenic effect of IgG4 autoantibodies in endemic pemphigus foliaceus (fogo selvagem). N Engl J Med 1989; 320:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/53\">",
"      Bhol K, Mohimen A, Ahmed AR. Correlation of subclasses of IgG with disease activity in pemphigus vulgaris. Dermatology 1994; 189 Suppl 1:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/54\">",
"      Frulloni L, Lunardi C, Simone R, et al. Identification of a novel antibody associated with autoimmune pancreatitis. N Engl J Med 2009; 361:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/55\">",
"      Kino-Ohsaki J, Nishimori I, Morita M, et al. Serum antibodies to carbonic anhydrase I and II in patients with idiopathic chronic pancreatitis and Sj&ouml;gren's syndrome. Gastroenterology 1996; 110:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/56\">",
"      Kim KP, Kim MH, Song MH, et al. Autoimmune chronic pancreatitis. Am J Gastroenterol 2004; 99:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/57\">",
"      Uchida K, Okazaki K, Konishi Y, et al. Clinical analysis of autoimmune-related pancreatitis. Am J Gastroenterol 2000; 95:2788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/58\">",
"      Deshpande V, Mino-Kenudson M, Brugge W, Lauwers GY. Autoimmune pancreatitis: more than just a pancreatic disease? A contemporary review of its pathology. Arch Pathol Lab Med 2005; 129:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/59\">",
"      Yoshida K, Toki F, Takeuchi T, et al. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci 1995; 40:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/60\">",
"      Nakazawa T, Ohara H, Sano H, et al. Cholangiography can discriminate sclerosing cholangitis with autoimmune pancreatitis from primary sclerosing cholangitis. Gastrointest Endosc 2004; 60:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/61\">",
"      Nakazawa T, Ohara H, Sano H, et al. Clinical differences between primary sclerosing cholangitis and sclerosing cholangitis with autoimmune pancreatitis. Pancreas 2005; 30:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/62\">",
"      Hirano K, Tada M, Isayama H, et al. Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut 2007; 56:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/63\">",
"      Moon SH, Kim MH, Park DH, et al. Is a 2-week steroid trial after initial negative investigation for malignancy useful in differentiating autoimmune pancreatitis from pancreatic cancer? A prospective outcome study. Gut 2008; 57:1704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/64\">",
"      Ito T, Nakano I, Koyanagi S, et al. Autoimmune pancreatitis as a new clinical entity. Three cases of autoimmune pancreatitis with effective steroid therapy. Dig Dis Sci 1997; 42:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/65\">",
"      Maire F, Le Baleur Y, Rebours V, et al. Outcome of patients with type 1 or 2 autoimmune pancreatitis. Am J Gastroenterol 2011; 106:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/66\">",
"      Sahani DV, Sainani NI, Deshpande V, et al. Autoimmune pancreatitis: disease evolution, staging, response assessment, and CT features that predict response to corticosteroid therapy. Radiology 2009; 250:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/67\">",
"      Kamisawa T, Egawa N, Nakajima H, et al. Morphological changes after steroid therapy in autoimmune pancreatitis. Scand J Gastroenterol 2004; 39:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/68\">",
"      Wakabayashi T, Kawaura Y, Satomura Y, et al. Long-term prognosis of duct-narrowing chronic pancreatitis: strategy for steroid treatment. Pancreas 2005; 30:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/69\">",
"      Topazian M, Witzig TE, Smyrk TC, et al. Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol 2008; 6:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40168/abstract/70\">",
"      Rueda JC, Duarte-Rey C, Casas N. Successful treatment of relapsing autoimmune pancreatitis in primary Sj&ouml;gren's syndrome with rituximab: report of a case and review of the literature. Rheumatol Int 2009; 29:1481.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5657 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-AFBC45AB80-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_14_40168=[""].join("\n");
var outline_f39_14_40168=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pancreatic manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Biliary tract manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1731730186\">",
"      Distinct clinical profiles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Serologic testing for IgG4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Anti-PBP peptide antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1684448\">",
"      Other antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61253267\">",
"      Distinction of IAC from PSC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Biliary strictures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Immunomodulatory drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/5657\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5657|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?24/62/25568\" title=\"diagnostic image 1\">",
"      AIP ERCP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5657|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/26/44451\" title=\"figure 1\">",
"      Pancreatograms AIP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5657|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/16/30976\" title=\"picture 1\">",
"      AIP Gross",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/13/37077\" title=\"picture 2A\">",
"      AIP infiltrate Light LP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/3/19509\" title=\"picture 2B\">",
"      AIP phlebitis Light LP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/58/7076\" title=\"picture 2C\">",
"      AIP phlebitis Light HP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/63/8179\" title=\"picture 2D\">",
"      AIP plasma cells Light LP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/60/38852\" title=\"picture 2E\">",
"      AIP plasma cells Light HP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/9/3220\" title=\"picture 2F\">",
"      AIP duct sclerosis Light HP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5657|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/43/36539\" title=\"table 1\">",
"      Spectrum of IgG4 systemic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/35/3643\" title=\"table 2\">",
"      Extrapancreatic manif AIP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/37/27227\" title=\"table 3\">",
"      AIP HISORt criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/35/17980\" title=\"table 4\">",
"      AIP response to treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22521?source=related_link\">",
"      Clinical manifestations and diagnosis of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/55/13178?source=related_link\">",
"      Overview of IgG4-related disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40058?source=related_link\">",
"      Treatment of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/8/41097?source=related_link\">",
"      Treatment of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_14_40169="Treatment of irritable bowel syndrome";
var content_f39_14_40169=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of irritable bowel syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/14/40169/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/14/40169/contributors\">",
"     Arnold Wald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/14/40169/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/14/40169/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/14/40169/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/14/40169/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/14/40169/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irritable bowel syndrome (IBS) is a gastrointestinal disorder characterized by chronic abdominal pain and altered bowel habits in the absence of any organic disorder. The approach to therapy of IBS will be reviewed here. The clinical manifestations and diagnosis of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/59/22455?source=see_link\">",
"     \"Clinical manifestations and diagnosis of irritable bowel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irritable bowel syndrome (IBS) is a chronic condition with no known cure. As a result, the focus of treatment should be on relief of symptoms and addressing the patient's concerns. An important question to answer is why the patient is seeking help at this time. Recent exacerbating factors (medications, dietary changes), concerns about serious illness, stressors, hidden agendas (disability claims, requests for opiates), or psychiatric comorbidities are critical to establish when developing the optimum therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Therapeutic relationship",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important component of treatment lies in the establishment of a therapeutic physician-patient relationship. The doctor should be non-judgmental, establish realistic expectations with consistent limits, and involve the patient in treatment decisions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with established, positive physician interactions have fewer IBS-related follow-up visits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of the therapeutic relationship in IBS was emphasized in a study that investigated the components of the placebo effect and patient-provider interaction in 262 patients with IBS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/3\">",
"     3",
"    </a>",
"    ]. Group 1 was assigned to a waitlist only, whereas Group 2 received sham acupuncture with little interaction with a health care provider (HCP). Group 3 received sham acupuncture but had much more interaction with a HCP. At both three and six weeks, the level of improvement in Group 3 was significantly better than Group 2, which in turn was significantly better than Group 1. The conclusion was that placebo effects are significant in IBS and that the patient-HCP interaction is the key part of that effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Education of the proposed mechanisms of IBS helps to validate the patient's illness experience and sets the basis for therapeutic interventions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/25/12697?source=see_link\">",
"     \"Pathophysiology of irritable bowel syndrome\"",
"    </a>",
"    .) Patients should be informed of the chronic and benign nature of IBS, and also informed that the diagnosis (if well-established) is not likely to be changed, and that he or she should have a normal life span. In a 29-year follow-up study of 112 patients from the Mayo Clinic, for example, only 10 of 112 patients developed an organic gastrointestinal disease; patient survival was similar to expected survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/53/3926?source=see_link\">",
"     \"Patient information: Irritable bowel syndrome (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Dietary modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful dietary history may reveal patterns of symptoms related to specific foods. A number of dietary interventions have been proposed but their efficacy has not been well established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Lactose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the similarity that may occur in symptoms of IBS and lactose intolerance, an empiric trial of a lactose free diet should be considered in patients suspected of having irritable bowel syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Some patients diagnosed with irritable bowel syndrome may have undiagnosed lactose intolerance and can have lasting clinical improvement when placed on a lactose restricted diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/32/5641?source=see_link\">",
"     \"Lactose intolerance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Exclusion of gas-producing foods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exclusion of foods that increase flatulence (beans, onions, celery, carrots, raisins, bananas, apricots, prunes, brussel sprouts, wheat germ, pretzels, and bagels) should be considered in patients who complain of gas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/6\">",
"     6",
"    </a>",
"    ]. Underlying visceral hyperalgesia in IBS may explain the exaggerated discomfort experienced with consumption of gas-producing foods. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/18/24872?source=see_link\">",
"     \"Intestinal gas and bloating\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/14/6371?source=see_link\">",
"     \"Patient information: Gas and bloating (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/25/12697?source=see_link\">",
"     \"Pathophysiology of irritable bowel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Food allergies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of food allergy in IBS is unclear. While it is possible that food allergy has a role in the development of symptoms, there are no reliable means to identify such individuals. Testing for serum immunoglobulins directed at specific dietary antigens (and elimination of responsible foods) has been proposed but the relationship between results of such testing and improvement of symptoms requires additional study before such an approach can be recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/7\">",
"     7",
"    </a>",
"    ]. Other methods used in evaluating food allergies (eg, skin prick testing, RAST testing and atopy patch testing) have not been well studied in IBS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Gluten sensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gluten sensitivity (without overt celiac disease) has been proposed as a cause of functional bowel disorders but there are few convincing studies that have evaluated such a relationship in terms of pathogenesis or treatment of IBS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. It is also unclear if gluten sensitivity is itself a separate clinical entity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/8,10-14\">",
"     8,10-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A trial of 34 patients examined the effect of a gluten-free diet in patients without celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/15\">",
"     15",
"    </a>",
"    ]. Patients were either HLA-DQ2 and HLA-DQ8 negative or had normal duodenal biopsies. Patients in the gluten arm received two gluten containing bread slices and one muffin per day, whereas the control patients received placebos. Patients in the gluten group were more likely to report inadequate symptom control compared with the placebo group (68 versus 40 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Carbohydrate malabsorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;One theory related to IBS (and inflammatory bowel disease [IBD]) suggests that symptoms may be at least in part related to impaired absorption of carbohydrates. The theory holds that fermentable oligo-, di-, and monosaccharides and polyols (FODMAPs) in patients with IBS or IBD enter the distal small bowel and colon where they are fermented, leading to symptoms and increased intestinal permeability (and possibly inflammation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some examples of FODMAPs include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fructans (found in wheat, onions, and artichokes)",
"     </li>",
"     <li>",
"      Galactans (found in legumes, cabbage, and Brussels' sprouts)",
"     </li>",
"     <li>",
"      Lactose",
"     </li>",
"     <li>",
"      Fructose",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/0/29699?source=see_link\">",
"       Sorbitol",
"      </a>",
"     </li>",
"     <li>",
"      Xylitol",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"       Mannitol",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Avoidance of carbohydrates has been a long-popularized non-pharmacologic approach to reducing symptoms in IBS (and possibly modifying disease in IBD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/17\">",
"     17",
"    </a>",
"    ] but there have been few contemporary studies. Fructose intolerance has been suggested as a possible form of carbohydrate malabsorption contributing to IBS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies examining FODMAP restriction in patients with IBS have suggested a clinical benefit:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial with 25 patients found that patients who were given fructose",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fructans were more likely to report inadequate symptom control compared with patients who were given glucose (70 to 79 percent versus 14 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/19\">",
"       19",
"      </a>",
"      ]. In addition, symptoms were induced in a dose-dependent manner and mimicked the patients&rsquo; previous IBS symptoms.",
"     </li>",
"     <li>",
"      A single-blind crossover trial gave 15 healthy volunteers and 15 patients with IBS diets that were either low (9",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      or high (50",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in FODMAPs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/20\">",
"       20",
"      </a>",
"      ]. Patients with IBS had a significant increase in gastrointestinal symptoms and lethargy while on the high FODMAPs diet, whereas healthy volunteers only reported increased flatus production while on the high FODMAPs diet.",
"     </li>",
"     <li>",
"      Another small crossover trial of patients with IBS-D found a clinical benefit with a very low carbohydrate diet (20 g of carbohydrates per day) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While diets low in FODMAPS have not been definitively shown to be of benefit, it is reasonable for patients to undergo a trial of a low FODMAPS diet, provided that their nutritional status is being monitored.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Fiber",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increase in the intake of fiber is often recommended, either through diet or the use of commercial bulking supplements. However, not all authorities agree. A systematic review found no beneficial effect for bulking agents over placebo for improvement of abdominal pain, global assessment or symptom scores. Subgroup analyses showed no significant benefit with either insoluble or soluble fibers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/22\">",
"     22",
"    </a>",
"    ]. A decrease in fiber intake to 12 g per day (particularly insoluble fiber such as bran) was suggested in a British guideline, because of the potential of fiber to exacerbate symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proposed mechanisms for fiber's beneficial effects include: enhancement of water holding properties of the stool; formation of gels to provide lubrication; bulking of the stool; and binding of agents such as bile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/24\">",
"     24",
"    </a>",
"    ]. Despite their widespread use, a systematic review that included 13 randomized controlled trials found no convincing evidence that the commonly-used bulking agents were more effective than placebo at relieving global IBS symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/25\">",
"     25",
"    </a>",
"    ]. Although the efficacy of fiber supplements has not been proven, some improvement has been demonstrated in patients with IBS whose primary complaints are abdominal pain and constipation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Synthetic fiber supplements such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/61/29651?source=see_link\">",
"     polycarbophil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/28/29123?source=see_link\">",
"     methylcellulose",
"    </a>",
"    are more soluble than natural fibers (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/26/8614?source=see_link\">",
"     psyllium",
"    </a>",
"    ). However, whether the synthetic supplements cause less bloating or are more effective than natural fiber supplements has not been determined. Some patients may experience increased bloating and gaseousness due to colonic metabolism of non-digestible fiber.",
"   </p>",
"   <p>",
"    Because of its safety and frequent placebo effect, a trial of fiber is reasonable in all patients with IBS, especially those with constipation-predominant symptoms. Dosages of fiber supplements such as wheat bran or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/26/8614?source=see_link\">",
"     psyllium",
"    </a>",
"    should be titrated to symptoms. Administration of one-half to one tablespoon once a day is a good starting dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64583454\">",
"    <span class=\"h2\">",
"     Physical activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased physical activity may help with the symptoms of IBS. This was examined in a randomized trial that assigned 102 patients to increased physical activity to maintenance of current activity levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/27\">",
"     27",
"    </a>",
"    ]. Increased physical activity was comprised of 20 to 60 minutes of moderate to vigorous activity three to five days per week. The amount of physical activity prescribed was determined in part by the patient&rsquo;s baseline level of activity. Seventy-five patients completed the study (38 in the physical activity arm and 37 in the control arm). After 12 weeks, there was a trend toward more patients in the physical activity arm showing clinical improvement in the severity of IBS symptoms compared with the control group (43 versus 26 percent, p = 0.07). In addition, patients in the physical activity arm were less likely to have clinically significant worsening of their IBS symptoms (8 versus 23 percent, p &lt;0.01).",
"   </p>",
"   <p>",
"    It is reasonable to recommend increased physical activity for patients with IBS given that these data suggest a potential benefit with regard to symptoms as well the general health benefits associated with increased physical activity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/46/28394?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of the benefits and risks of exercise\", section on 'Benefits of exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Psychosocial therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavioral treatments may be considered for motivated patients who associate symptoms with stressors, although their benefits remain controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/1,28\">",
"     1,28",
"    </a>",
"    ]. Hypnosis, biofeedback, and psychotherapy help to reduce anxiety levels, encourage health promoting behavior, increase patient responsibility and involvement in the treatment, and improve pain tolerance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2009 meta-analysis that included 20 placebo-controlled trials of antidepressants in 1278 adults with IBS concluded that psychological therapy was significantly more effective than control therapy or usual management for at least a 50 percent reduction in symptoms (relative risk of IBS symptoms persisting 0.67, 95% CI 0.57 to 0.79) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/30\">",
"     30",
"    </a>",
"    ]. A similar conclusion was reached by the 2009 position statement on IBS by the American College of Gastroenterology Task Force on Irritable Bowel Syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/25\">",
"     25",
"    </a>",
"    ]. A lesser benefit was noted in another systematic review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of benefit from psychosocial therapies is unclear. In one randomized controlled trial, mindfulness training, a cognitive behavioral technique, reduced IBS symptom severity, improved health-related quality of life, and reduced distress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/32\">",
"     32",
"    </a>",
"    ]. However, in another randomized trial, symptom improvement was independent of the effects of cognitive behavioral therapy in alleviating comorbid psychological distress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic agents are only an",
"    <strong>",
"     adjunct",
"    </strong>",
"    to treatment in irritable bowel syndrome (IBS). Furthermore, the drug chosen varies depending on the patient's major symptoms; diarrhea-predominant IBS is treated differently from constipation-predominant disease.",
"   </p>",
"   <p>",
"    We suggest that the chronic use of drugs be generally minimized or avoided because of the lifelong nature of this disorder and the lack of convincing therapeutic benefit. The difficulty in demonstrating efficacy may in part be due to the heterogeneous population diagnosed with IBS, the lack of disease markers, and the high placebo response rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Antispasmodic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antispasmodic agents are the most frequently used pharmacologic agents in the treatment of IBS. Certain antispasmodic drugs (hyoscine, cimetropium, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/17/41234?source=see_link\">",
"     pinaverium",
"    </a>",
"    ) may provide short-term relief but long-term efficacy has not been demonstrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/25\">",
"     25",
"    </a>",
"    ]. Peppermint oil may also act as a smooth muscle relaxant (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Alternative therapies'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The antispasmodic agents include those that directly affect intestinal smooth muscle relaxation (eg, mebeverine and pinaverine), and those that act via their anticholinergic or antimuscarinic properties (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/6/27749?source=see_link\">",
"     dicyclomine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/9/29846?source=see_link\">",
"     hyoscyamine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/25\">",
"     25",
"    </a>",
"    ]. The selective inhibition of gastrointestinal smooth muscle reduces stimulated colonic motor activity and may be beneficial in patients with postprandial abdominal pain, gas, bloating, and fecal urgency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of 23 controlled trials of smooth muscle relaxants found that they were more effective than placebo (risk difference for global improvement of 22 percent, and overall pain improvement of 53 versus 41 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/36\">",
"     36",
"    </a>",
"    ]. Only weak evidence for a benefit on abdominal pain and global assessment of symptoms was suggested in a second meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/37\">",
"     37",
"    </a>",
"    ]. A systematic review confirmed the support for short-term use of some antispasmodic drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/25\">",
"     25",
"    </a>",
"    ]. In another systematic review, subgroup analyses of different types of antispasmodics found statistically significant benefits for",
"    <span class=\"nowrap\">",
"     cimetropium/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?27/6/27749?source=see_link\">",
"      dicyclomine",
"     </a>",
"     ,",
"    </span>",
"    peppermint oil,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/17/41234?source=see_link\">",
"     pinaverium",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33458?source=see_link\">",
"     trimebutine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Administration of these medications in the treatment of IBS should be on an as needed basis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in anticipation of stressors with known exacerbating effects. Typical doses include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/6/27749?source=see_link\">",
"       Dicyclomine",
"      </a>",
"      20 mg orally four times daily as needed",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/9/29846?source=see_link\">",
"       Hyoscyamine",
"      </a>",
"      0.125 to 0.25 mg orally or sublingually three to four times daily as needed",
"     </li>",
"     <li>",
"      Sustained release",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/9/29846?source=see_link\">",
"       hyoscyamine",
"      </a>",
"      0.375 to 0.75 mg orally every 12 hours",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antidepressants have analgesic properties independent of their mood improving effects and may therefore be beneficial in patients with neuropathic pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. The postulated mechanisms of pain modulation with tricyclic antidepressants (TCAs) and possibly serotonin reuptake inhibitors (SSRIs) in IBS are facilitation of endogenous endorphin release, blockade of norepinephrine reuptake leading to enhancement of descending inhibitory pain pathways, and blockade of the pain neuromodulator, serotonin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. TCAs, via their anticholinergic properties, also slow intestinal transit time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/41\">",
"     41",
"    </a>",
"    ], which may provide benefit in diarrhea-predominant IBS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2009 meta-analysis that included 13 placebo-controlled trials of antidepressants in 789 adults with IBS concluded that antidepressants were significantly more effective than placebo for the relief of pain and global symptoms (relative risk of IBS symptoms persisting 0.66, 95% CI 0.57-0.78) at a duration of therapy ranging from one to three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/30\">",
"     30",
"    </a>",
"    ]. The number need to treat to benefit one patient was four. The treatment effects were similar for SSRIs and tricyclic antidepressants. A similar conclusion was reached in a 2009 position statement from the American College of Gastroenterology Task Force on Irritable Bowel Syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/25\">",
"     25",
"    </a>",
"    ] and in a subsequent systematic review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By contrast, antidepressant efficacy is unproven in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/44\">",
"     44",
"    </a>",
"    ]. This was illustrated in a multicenter trial of 83 children with functional gastrointestinal disorders who were randomly assigned to an antidepressant or placebo for four weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/45\">",
"     45",
"    </a>",
"    ]. The primary end point was the child's assessment of pain relief and sense of improvement. At four weeks, there was no significant difference between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    and placebo in the frequency of attaining the primary end point (63 versus 58 percent, p = 0.85). The authors noted that a longer period of treatment and a higher dose of antidepressant may have produced different results and that there may be a large placebo effect in children due to multiple factors. In another trial of 33 adolescents assigned to an antidepressant or placebo, an antidepressant was effective in reducing diarrhea and pain after a longer period of treatment (6, 8, and 13 weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Improvement in neuropathic pain with TCAs occurs at lower doses than required for treatment of depression. As a result, if an antidepressant is chosen for the treatment of IBS, low doses should be administered initially and titrated to pain control or tolerance. Because of the delayed onset of action, three to four weeks of therapy should be attempted before considering treatment insufficient and increasing the dose.",
"   </p>",
"   <p>",
"    Examples of antidepressant medications used in patients with IBS include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    . The initial dose should be adjusted based upon tolerance and response. TCAs should be used cautiously in patients with constipation. Amitriptyline, nortriptyline, and imipramine can be started at a dose of 10 to 25 mg at bedtime and increased every three to four weeks based upon clinical response and tolerance. Desipramine is used in a similar fashion beginning at 12.5 to 25 mg at bedtime. If the patient is intolerant of one TCA, another may be tried.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     Paroxetine",
"    </a>",
"    (10 to 20 mg daily),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    (20 to 40 mg daily),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    (50 to 100 mg daily), or other antidepressant medications can be considered if depression is a cofactor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is less published experience with other antidepressants such as SSRIs or serotonin norepinephrine reuptake inhibitors (SNRIs), although they are used clinically. Results of the few published trials (mainly with SSRIs) have been inconsistent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/47-52\">",
"     47-52",
"    </a>",
"    ]. As noted above, one meta-analysis concluded that overall treatment effects were similar to tricyclic antidepressants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/30\">",
"     30",
"    </a>",
"    ]. Subgroup analyses in a systematic review demonstrated a statistically significant improvement in global assessment scores with SSRIs and an improvement in abdominal pain and symptom scores with TCAs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Antidiarrheal agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;In diarrhea-prone patients with IBS, the stools characteristically are loose and frequent but of normal total daily volume. A systematic review identified three controlled trials evaluating",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/53/16214?source=see_link\">",
"     loperamide",
"    </a>",
"    in the treatment of IBS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/25,53-55\">",
"     25,53-55",
"    </a>",
"    ]. All were of short duration, enrolled a small number of patients, and did not use standardized criteria for identifying patients. Overall, the trials suggested that loperamide was more effective than placebo for treatment of diarrhea, but not for treatment of global IBS symptoms or abdominal pain. Administration on an as needed basis is preferred to a regular scheduled dosing in patients with diarrhea. Patients who consistently develop diarrhea after meals may benefit from taking a dose before meals. Loperamide should not be used in patients with constipation and should be used only cautiously in those with symptoms alternating between diarrhea and constipation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anxiolytic agents are of",
"    <strong>",
"     limited",
"    </strong>",
"    usefulness in IBS because of the risk of drug interactions, habituation, and rebound withdrawal. Furthermore, benzodiazepines may lower pain thresholds by stimulating gamma aminobutyric acid (GABA) receptors, thereby decreasing brain serotonin. They may, however, be useful for short-term (less than two weeks') reduction of acute situational anxiety that may be contributing to symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     5-hydroxytryptamine (serotonin) 3 receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;5-hydroxytryptamine-3 receptor antagonists (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"     alosetron",
"    </a>",
"    , cilansetron,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32550?source=see_link\">",
"     granisetron",
"    </a>",
"    ) modulate visceral afferent activity from the gastrointestinal tract and may improve abdominal pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. A meta-analysis that included 14 randomized controlled trials in IBS (involving alosetron or cilansetron,) found a benefit in global improvement in IBS and relief of abdominal pain and discomfort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/61/8149?source=see_link\">",
"     Alosetron",
"    </a>",
"    was developed for use in IBS based upon its favorable effects on colonic motility and secretion and on afferent neural systems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/59\">",
"     59",
"    </a>",
"    ]. In clinical trials the drug was most effective in female patients in whom diarrhea was predominant. However, the drug was associated with ischemic colitis and serious complications related to severe constipation, prompting the Food and Drug Administration (FDA) to remove it from the market in the United States. Evaluation of post-marketing data and demand from a subset of patients who had responded to treatment has prompted the FDA to bring the drug back to the market under tight control. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/52/38727?source=see_link\">",
"     \"Alosetron hydrochloride (Lotronex) for irritable bowel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     5-hydroxytryptamine (serotonin) 4 receptor agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agonists of the 5-hydroxytryptamine-4 (5-HT4) receptor stimulate the release of neurotransmitters and increase colonic motility, providing a rationale for their use in constipation predominant IBS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/60\">",
"     60",
"    </a>",
"    ]. The first of this class of drugs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/4/4164?source=see_link\">",
"     tegaserod",
"    </a>",
"    {Zelnorm}, a partial 5-HT4 receptor agonist) was approved for IBS and constipation but removed from the market in March 2007 because of cardiovascular side-effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Lubiprostone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/28/38339?source=see_link\">",
"     Lubiprostone",
"    </a>",
"    is a locally acting chloride channel activator that enhances chloride-rich intestinal fluid secretion. Lubiprostone has been approved by the United States Food and Drug Administration for treatment of irritable bowel syndrome with constipation in women 18 years and older. However, its role continues to be determined. There have been no comparisons with other options for treatment of IBS with constipation and its long-term safety remains to be established. Furthermore, the placebo response in the studies above was far lower than most studies of IBS and it is not intuitive why a secretory agent would improve symptoms other than constipation in a disorder such as IBS. Until further data are available (and because it is expensive compared with other options), it is best reserved for patients with IBS and severe constipation in whom other approaches have been unsuccessful.",
"   </p>",
"   <p>",
"    Approval was based upon two multicenter placebo-controlled trials involving 1154 adults (92 percent women) with irritable bowel syndrome and constipation who were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/28/38339?source=see_link\">",
"     lubiprostone",
"    </a>",
"    (8 micrograms twice daily) or placebo for 12 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/61\">",
"     61",
"    </a>",
"    ]. Patients randomized to lubiprostone were significantly more likely to achieve an overall response (18 versus 10 percent). Serious adverse events were similar to placebo. The most common adverse event was nausea (8 versus 4 percent). A follow-up open-label study involving 522 patients showed that benefits continued or improved at 52 weeks. The approved dose (8 micrograms twice daily) is lower than the approved dose for treatment of chronic idiopathic constipation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Guanylate cyclase agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/17/20755?source=see_link\">",
"     Linaclotide",
"    </a>",
"    is a guanylate cyclase agonist that stimulates intestinal fluid secretion and transit. Linaclotide has been approved by the US Food and Drug Administration for treatment of IBS with constipation at a dose of 290 micrograms daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/62\">",
"     62",
"    </a>",
"    ]. However, the long-term risks of linaclotide are unknown and therefore its role on the treatment of IBS with constipation remains to be determined. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Approval was based upon two randomized controlled phase III trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. In one randomized controlled trial, 800 patients with IBS with constipation were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/17/20755?source=see_link\">",
"     linaclotide",
"    </a>",
"    (266 micrograms daily) or placebo for 12 weeks followed by a four-week withdrawal period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/63\">",
"     63",
"    </a>",
"    ]. During the withdrawal period, patients previously randomized to placebo received linaclotide, and patients who originally received linaclotide were randomized to either linaclotide or placebo. After 12 weeks, the percentage of patients meeting the composite endpoint (&ge;30 percent reduction in abdominal pain, &ge;3 complete and spontaneous bowel movements (CSBM), increase in &ge;1 CSBM from baseline; in the same week) was significantly greater with linaclotide compared with placebo (34 versus 21 percent). Patients who received linaclotide also demonstrated a significant improvement in secondary endpoints of abdominal",
"    <span class=\"nowrap\">",
"     pain/discomfort,",
"    </span>",
"    bloating, straining, stool consistency, number of CSBMs and spontaneous bowel movements per week, compared with placebo. After the initial 12 weeks, patients originally given linaclotide and who remained on linaclotide showed sustained improvement in abdominal pain, but patients who were switched to placebo experienced recurrence of abdominal pain. Patients initially randomized to placebo had significant improvement in abdominal pain within one week after being switched to linaclotide. Diarrhea was the most common side effect causing discontinuation of treatment in 5.7 percent of patients treated with linaclotide compared with 0.3 percent in patients receiving with placebo. A second randomized controlled trial assessed the efficacy of long-term use of linaclotide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/64\">",
"     64",
"    </a>",
"    ]. In this trial, 804 patients with IBS with constipation were randomly assigned to receive linaclotide (266 micrograms daily) or placebo for 26 weeks. Patients randomized to linaclotide demonstrated a significant improvement in the same composite primary endpoint compared with placebo (38 versus 14 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5845072\">",
"    <span class=\"h2\">",
"     Mast cell stabilizers",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33024?source=see_link\">",
"     Ketotifen",
"    </a>",
"    is a mast cell stabilizer that has been studied for the treatment of IBS based upon the theory that mast cell activation contributes to visceral hypersensitivity. In a randomized trial of 60 patients, the use of ketotifen for eight weeks increased the threshold for discomfort with rectal distension in patients who were hypersensitive to rectal balloon distension at baseline, but not in those with normal sensitivity at baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/65\">",
"     65",
"    </a>",
"    ]. While there was a suggestion of symptom improvement in patients who received ketotifen compared with those who received placebo, the results did not reach statistical significance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with IBS have shown improvement when treated with antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/66-70\">",
"     66-70",
"    </a>",
"    ]. Most of the improvement has been in symptoms of bloating, abdominal pain, or altered bowel habits.",
"   </p>",
"   <p>",
"    In a report of two randomized trials (TARGET 1 and TARGET 2) with 1260 patients with IBS without constipation,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/17/37140?source=see_link\">",
"     rifaximin",
"    </a>",
"    , a nonabsorbable antibiotic, led to symptomatic improvement in global IBS symptoms and bloating [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/70\">",
"     70",
"    </a>",
"    ]. Patients were assigned to receive either rifaximin 550 mg three times daily or placebo for a total of 14 days and were then followed for 10 weeks. During the first four weeks of follow-up, patients who received rifaximin were more likely to report adequate relief of IBS symptoms than patients who received placebo (41 versus 32 percent). They also were more likely to report adequate relief of bloating (40 versus 30 percent). Patients who received rifaximin continued to report better symptom relief during the remainder of the follow-up period. In a meta-analysis of five randomized controlled trials, rifaximin was more efficacious than placebo for global IBS symptom improvement (OR 1.57) and was significantly more likely to be associated with decreased bloating than placebo (OR 1.55) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms leading to the benefit are unclear but may be due to suppression of gas producing bacteria in the colon. Such studies do not prove the hypothesis that bacterial overgrowth in the small intestine underlies the symptoms of most patients with IBS. Furthermore, in one report,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    breath testing (the method used for suggesting bacterial overgrowth in some of these studies) did not discriminate patients with IBS from healthy controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/72\">",
"     72",
"    </a>",
"    ]. Thus, the relationships between bacterial overgrowth, benefits of antibiotics in patients with IBS, and methods to test for bacterial overgrowth in IBS require further study.",
"   </p>",
"   <p>",
"    Given the modest benefit and relatively short-term follow-up demonstrated in the trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/17/37140?source=see_link\">",
"     rifaximin",
"    </a>",
"    , we do not suggest the routine use of antibiotics in patients with IBS. However, in patients with moderate to severe IBS without constipation (particularly those with bloating) who have failed to respond to all other therapies, including a low carbohydrate diet and elimination of fermentable oligo-, di-, and monosaccharides and polyols (FODMAPs), it is reasonable to consider two-week trial of rifaximin (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Carbohydrate malabsorption'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Alternative therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple alternative forms of therapy for IBS have been suggested, such as herbs, probiotics, acupuncture, and enzyme supplementation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/73-76\">",
"     73-76",
"    </a>",
"    ]. Their role remains uncertain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16554?source=see_link&amp;anchor=H9#H9\">",
"     \"Probiotics for gastrointestinal diseases\", section on 'Irritable bowel syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Peppermint oil has been studied in randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial included 90 patients with irritable bowel syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/77\">",
"       77",
"      </a>",
"      ]. Patients were assigned to receive either a delayed release capsule with 187 mg of peppermint oil or placebo three times daily 30 minutes before meals for eight weeks. At baseline, the most common symptoms were abdominal pain, distention, and flatulence. Sixty patients completed the study (33 in the treatment arm and 27 in the control arm). At the end of the study, more patients in the treatment arm who completed the study reported being free from abdominal pain or discomfort (43 versus 22 percent in the per protocol analysis, 31 versus 13 percent in the intention to treat analysis).",
"     </li>",
"     <li>",
"      A second trial included 57 patients and assigned the patients to 225 mg of peppermint oil (28 patients) or placebo (29 patients) twice daily for four weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/78\">",
"       78",
"      </a>",
"      ]. The loss to follow-up in this trial was less than in the first (11 percent in the treatment arm and 10 percent in the control arm). After four weeks of treatment, more patients in the treatment arm reported at least a 50 percent reduction in symptoms than in the control arm (75 versus 38 percent in the per protocol analysis, 64 versus 34 percent in the intention to treat analysis).",
"     </li>",
"     <li>",
"      A third trial included 110 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/79\">",
"       79",
"      </a>",
"      ]. Patients were assigned to 187 mg of peppermint oil or placebo three to four times daily before meals for one month. Fifty-two patients in the treatment arm (95 percent) and 49 patients in the control arm (89 percent) completed the trial. At the end of the trial, more patients in the treatment arm were pain free (56 versus 8 percent in per protocol analysis, 53 versus 7 percent in the intention to treat analysis). Patients in the treatment arm also reported more improvement in pain severity, abdominal distention, stool frequency (decreased), borborygmi, and flatulence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     MAJOR SOCIETY GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for the management of irritable bowel syndrome (IBS) have been issued by several organizations. The 2009 position statement from the American College of Gastroenterology Task Force on Irritable Bowel Syndrome includes recommendations on the role of dietary modification, medications, psychological and alternative therapies in the treatment of IBS (",
"    <a class=\"graphic graphic_table graphicRef77027 \" href=\"mobipreview.htm?37/21/38237\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/14/40169/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/34/31265?source=see_link\">",
"       \"Patient information: Irritable bowel syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/53/3926?source=see_link\">",
"       \"Patient information: Irritable bowel syndrome (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/39/8817?source=see_link\">",
"       \"Patient information: High-fiber diet (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of irritable bowel syndrome (IBS) varies with the severity and type (diarrhea versus constipation predominant) of symptoms that are present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Mild symptoms",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with mild or infrequent symptoms usually have little or no functional impairment or psychologic disturbance. Thus, we suggest treatment should focus upon the general measures described above (such as establishment of the physician-patient relationship, patient education, reassurance, dietary modification, and, if bloating is not a major factor, fiber supplementation) rather than specific pharmacologic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Moderate symptoms",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with moderate symptoms of IBS experience disruptions of normal daily activities due to exacerbations of symptoms; these patients also may demonstrate psychologic impairment.",
"     </li>",
"     <li>",
"      We monitor patients' symptoms for several weeks to help identify precipitating factors, such as lactose intolerance, excess caffeine, or specific stressors. Modifications in diet, behavioral changes, and psychotherapy may improve the clinical outcome.",
"     </li>",
"     <li>",
"      Randomized controlled trials evaluating specific pharmacologic agents have demonstrated their superiority compared with placebo. However, there have been few controlled trials evaluating specific strategies for how these drugs should be used in conjunction with other types of treatment (such as fiber therapy), how long they should be used, or whether they should be given continuously or episodically. We often use pharmacologic intervention to control symptom flares but also use continuous pharmacologic therapy (such as tricyclic antidepressant drugs) for periods of months or years. Our choice of specific therapies is based mainly upon symptoms and response to empiric trials (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Medications'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Given the modest benefit and relatively short-term follow-up demonstrated in the trials of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/17/37140?source=see_link\">",
"       rifaximin",
"      </a>",
"      , we suggest NOT using antibiotics routinely in patients with IBS (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, in patients with moderate to severe IBS without constipation (particularly those with bloating) who have failed to respond to all other therapies, including a low carbohydrate diet and elimination of fermentable oligo-, di-, and monosaccharides and polyols (FODMAPs), it is reasonable to consider a two-week trial of rifaximin. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Antibiotics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Carbohydrate malabsorption'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Intractable symptoms",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A small subset of patients with IBS present to tertiary care centers with severe, unrelenting symptoms that are often associated with underlying psychiatric impairment and frequent health care utilization. We suggest behavioral modification and the use of psychoactive drugs in such patients (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Medications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/1\">",
"      Drossman DA, Thompson WG. The irritable bowel syndrome: review and a graduated multicomponent treatment approach. Ann Intern Med 1992; 116:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/2\">",
"      Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann Intern Med 1995; 122:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/3\">",
"      Kaptchuk TJ, Kelley JM, Conboy LA, et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 2008; 336:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/4\">",
"      Vesa TH, Seppo LM, Marteau PR, et al. Role of irritable bowel syndrome in subjective lactose intolerance. Am J Clin Nutr 1998; 67:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/5\">",
"      B&ouml;hmer CJ, Tuynman HA. The effect of a lactose-restricted diet in patients with a positive lactose tolerance test, earlier diagnosed as irritable bowel syndrome: a 5-year follow-up study. Eur J Gastroenterol Hepatol 2001; 13:941.",
"     </a>",
"    </li>",
"    <li>",
"     Hasler WL, Owyang C. Irritable bowel syndrome. In: Textbook of Gastroenterology, 4th ed, Yamada T (Ed), JB Lippincott, Philadelphia 2003. p.1817.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/7\">",
"      Atkinson W, Sheldon TA, Shaath N, Whorwell PJ. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut 2004; 53:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/8\">",
"      Verdu EF, Armstrong D, Murray JA. Between celiac disease and irritable bowel syndrome: the \"no man's land\" of gluten sensitivity. Am J Gastroenterol 2009; 104:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/9\">",
"      Wahnschaffe U, Ullrich R, Riecken EO, Schulzke JD. Celiac disease-like abnormalities in a subgroup of patients with irritable bowel syndrome. Gastroenterology 2001; 121:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/10\">",
"      Cooper BT, Holmes GK, Ferguson R, et al. Gluten-sensitive diarrhea without evidence of celiac disease. Gastroenterology 1980; 79:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/11\">",
"      Kaukinen K, Turjanmaa K, M&auml;ki M, et al. Intolerance to cereals is not specific for coeliac disease. Scand J Gastroenterol 2000; 35:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/12\">",
"      Sapone A, Lammers KM, Mazzarella G, et al. Differential mucosal IL-17 expression in two gliadin-induced disorders: gluten sensitivity and the autoimmune enteropathy celiac disease. Int Arch Allergy Immunol 2010; 152:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/13\">",
"      Bizzaro N, Tozzoli R, Villalta D, et al. Cutting-edge issues in celiac disease and in gluten intolerance. Clin Rev Allergy Immunol 2012; 42:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/14\">",
"      Volta U, Tovoli F, Cicola R, et al. Serological tests in gluten sensitivity (nonceliac gluten intolerance). J Clin Gastroenterol 2012; 46:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/15\">",
"      Biesiekierski JR, Newnham ED, Irving PM, et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol 2011; 106:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/16\">",
"      Gibson PR, Shepherd SJ. Personal view: food for thought--western lifestyle and susceptibility to Crohn's disease. The FODMAP hypothesis. Aliment Pharmacol Ther 2005; 21:1399.",
"     </a>",
"    </li>",
"    <li>",
"     Gottschall E. Breaking the Viscious Cycle. In: The Specific Carbohydrate Diet(TM), Kirkton Press Limited, 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/18\">",
"      Choi YK, Johlin FC Jr, Summers RW, et al. Fructose intolerance: an under-recognized problem. Am J Gastroenterol 2003; 98:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/19\">",
"      Shepherd SJ, Parker FC, Muir JG, Gibson PR. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol 2008; 6:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/20\">",
"      Ong DK, Mitchell SB, Barrett JS, et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol 2010; 25:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/21\">",
"      Austin GL, Dalton CB, Hu Y, et al. A very low-carbohydrate diet improves symptoms and quality of life in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2009; 7:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/22\">",
"      Ruepert L, Quartero AO, de Wit NJ, et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2011; :CD003460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/23\">",
"      Dalrymple J, Bullock I. Diagnosis and management of irritable bowel syndrome in adults in primary care: summary of NICE guidance. BMJ 2008; 336:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/24\">",
"      Friedman G. Diet and the irritable bowel syndrome. Gastroenterol Clin North Am 1991; 20:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/25\">",
"      American College of Gastroenterology Task Force on Irritable Bowel Syndrome, Brandt LJ, Chey WD, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/26\">",
"      Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 1997; 112:2120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/27\">",
"      Johannesson E, Simr&eacute;n M, Strid H, et al. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol 2011; 106:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/28\">",
"      Lackner JM, Jaccard J, Krasner SS, et al. Self-administered cognitive behavior therapy for moderate to severe irritable bowel syndrome: clinical efficacy, tolerability, feasibility. Clin Gastroenterol Hepatol 2008; 6:899.",
"     </a>",
"    </li>",
"    <li>",
"     Drossman DA, Chang L. Psychosocial factors in the care of patients with gastrointestinal disorders. In: Textbook of Gastroenterology, 4th ed, Yamada T (Ed), JB Lippincott, Philadelphia 2003. p.636.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/30\">",
"      Ford AC, Talley NJ, Schoenfeld PS, et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/31\">",
"      Zijdenbos IL, de Wit NJ, van der Heijden GJ, et al. Psychological treatments for the management of irritable bowel syndrome. Cochrane Database Syst Rev 2009; :CD006442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/32\">",
"      Gaylord SA, Palsson OS, Garland EL, et al. Mindfulness training reduces the severity of irritable bowel syndrome in women: results of a randomized controlled trial. Am J Gastroenterol 2011; 106:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/33\">",
"      Lackner JM, Jaccard J, Krasner SS, et al. How does cognitive behavior therapy for irritable bowel syndrome work? A mediational analysis of a randomized clinical trial. Gastroenterology 2007; 133:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/34\">",
"      Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000; 133:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/35\">",
"      Lynn RB, Friedman LS. Irritable bowel syndrome. N Engl J Med 1993; 329:1940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/36\">",
"      Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001; 15:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/37\">",
"      Quartero AO, Meineche-Schmidt V, Muris J, et al. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2005; :CD003460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/38\">",
"      Eisendrath SJ, Kodama KT. Fluoxetine management of chronic abdominal pain. Psychosomatics 1992; 33:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/39\">",
"      Hameroff SR, Weiss JL, Lerman JC, et al. Doxepin's effects on chronic pain and depression: a controlled study. J Clin Psychiatry 1984; 45:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/40\">",
"      Pilowsky I, Barrow CG. A controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain. Pain 1990; 40:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/41\">",
"      Gorard DA, Libby GW, Farthing MJ. Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome. Dig Dis Sci 1995; 40:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/42\">",
"      Bueno L, Fioramonti J, Delvaux M, Frexinos J. Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Gastroenterology 1997; 112:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/43\">",
"      Clouse RE, Lustman PJ, Geisman RA, Alpers DH. Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther 1994; 8:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/44\">",
"      Kaminski A, Kamper A, Thaler K, et al. Antidepressants for the treatment of abdominal pain-related functional gastrointestinal disorders in children and adolescents. Cochrane Database Syst Rev 2011; :CD008013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/45\">",
"      Saps M, Youssef N, Miranda A, et al. Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders. Gastroenterology 2009; 137:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/46\">",
"      Bahar RJ, Collins BS, Steinmetz B, Ament ME. Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents. J Pediatr 2008; 152:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/47\">",
"      Tabas G, Beaves M, Wang J, et al. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol 2004; 99:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/48\">",
"      Tack J, Broekaert D, Fischler B, et al. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006; 55:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/49\">",
"      Kuiken SD, Tytgat GN, Boeckxstaens GE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 2003; 1:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/50\">",
"      Vahedi H, Merat S, Rashidioon A, et al. The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Aliment Pharmacol Ther 2005; 22:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/51\">",
"      Creed F, Fernandes L, Guthrie E, et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003; 124:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/52\">",
"      Ladabaum U, Sharabidze A, Levin TR, et al. Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2010; 8:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/53\">",
"      Cann PA, Read NW, Holdsworth CD, Barends D. Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci 1984; 29:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/54\">",
"      Hovdenak N. Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol Suppl 1987; 130:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/55\">",
"      Efskind PS, Bernklev T, Vatn MH. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 1996; 31:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/56\">",
"      Zighelboim J, Talley NJ, Phillips SF, et al. Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism. Dig Dis Sci 1995; 40:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/57\">",
"      Prior A, Read NW. Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1993; 7:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/58\">",
"      Andresen V, Montori VM, Keller J, et al. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 2008; 6:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/59\">",
"      Gershon MD. Serotonin and its implication for the management of irritable bowel syndrome. Rev Gastroenterol Disord 2003; 3 Suppl 2:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/60\">",
"      Scott LJ, Perry CM. Tegaserod. Drugs 1999; 58:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/61\">",
"      Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009; 29:329.",
"     </a>",
"    </li>",
"    <li>",
"     FDA approves Linzess to treat certain cases of irritable bowel syndrome and constipation. Available at: file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm317505.htm (Accessed on September 04, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/63\">",
"      Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012; 107:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/64\">",
"      Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012; 107:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/65\">",
"      Klooker TK, Braak B, Koopman KE, et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010; 59:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/66\">",
"      Nayak AK, Karnad DR, Abraham P, Mistry FP. Metronidazole relieves symptoms in irritable bowel syndrome: the confusion with so-called 'chronic amebiasis'. Indian J Gastroenterol 1997; 16:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/67\">",
"      Sharara AI, Aoun E, Abdul-Baki H, et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006; 101:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/68\">",
"      Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003; 98:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/69\">",
"      Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006; 145:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/70\">",
"      Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/71\">",
"      Menees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2012; 107:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/72\">",
"      Bratten JR, Spanier J, Jones MP. Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls. Am J Gastroenterol 2008; 103:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/73\">",
"      Spanier JA, Howden CW, Jones MP. A systematic review of alternative therapies in the irritable bowel syndrome. Arch Intern Med 2003; 163:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/74\">",
"      Liu JP, Yang M, Liu YX, et al. Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2006; :CD004116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/75\">",
"      Lembo AJ, Conboy L, Kelley JM, et al. A treatment trial of acupuncture in IBS patients. Am J Gastroenterol 2009; 104:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/76\">",
"      Manheimer E, Cheng K, Wieland LS, et al. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2012; 5:CD005111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/77\">",
"      Merat S, Khalili S, Mostajabi P, et al. The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci 2010; 55:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/78\">",
"      Cappello G, Spezzaferro M, Grossi L, et al. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. Dig Liver Dis 2007; 39:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/14/40169/abstract/79\">",
"      Liu JH, Chen GH, Yeh HZ, et al. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol 1997; 32:765.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2631 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-AF04787F30-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_14_40169=[""].join("\n");
var outline_f39_14_40169=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Therapeutic relationship",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Patient education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Dietary modification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Lactose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Exclusion of gas-producing foods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Food allergies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Gluten sensitivity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Carbohydrate malabsorption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Fiber",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64583454\">",
"      Physical activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Psychosocial therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Antispasmodic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Antidiarrheal agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      5-hydroxytryptamine (serotonin) 3 receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      5-hydroxytryptamine (serotonin) 4 receptor agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Lubiprostone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Guanylate cyclase agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5845072\">",
"      Mast cell stabilizers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Alternative therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      MAJOR SOCIETY GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Mild symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Moderate symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Intractable symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2631\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2631|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/21/38237\" title=\"table 1\">",
"      ACG Rx IBS 2009",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/52/38727?source=related_link\">",
"      Alosetron hydrochloride (Lotronex) for irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/59/22455?source=related_link\">",
"      Clinical manifestations and diagnosis of irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=related_link\">",
"      Diagnostic evaluation of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/18/24872?source=related_link\">",
"      Intestinal gas and bloating",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/32/5641?source=related_link\">",
"      Lactose intolerance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/46/28394?source=related_link\">",
"      Overview of the benefits and risks of exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/25/12697?source=related_link\">",
"      Pathophysiology of irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/14/6371?source=related_link\">",
"      Patient information: Gas and bloating (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/39/8817?source=related_link\">",
"      Patient information: High-fiber diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/53/3926?source=related_link\">",
"      Patient information: Irritable bowel syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/34/31265?source=related_link\">",
"      Patient information: Irritable bowel syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16554?source=related_link\">",
"      Probiotics for gastrointestinal diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_14_40170="Squamous CA keratin Light";
var content_f39_14_40170=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72421%7EPULM%2F73209%7EPULM%2F51629%7EPULM%2F56588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72421%7EPULM%2F73209%7EPULM%2F51629%7EPULM%2F56588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Keratinization in lung cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 398px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Keratin (arrow) appears as waxy, darkly staining eosinophilic cytoplasm in this high powered photomicrograph of a well differentiated squamous cell carcinoma of the lung.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Keratinization in lung cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 318px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low magnification photomicrograph showing marked keratinization in a squamous cell carcinoma of the lung.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Squamous cell carcinoma of the lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cytology specimen showing the typical appearance of squamous cell carcinoma of the lung. The malignant cell has an enlarged hyperchromatic nucleus and darkly staining cytoplasm with an irregular configuration including a cytoplasmic tail (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Exophytic squamous cell carcinoma of the lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 401px; height: 303px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEvAZEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6L83nINSK9Vl7ZqyBxmszmsP3e5oJJ70LggZpxWhlJEbSEKQuc0kbEY9e9PKgUmKzbRSRKGJwacGOeaiHSnA1N12KSY7dk0mTn29KTdzzR1oTQWHFzQHb1ptAzmmrBZihsN70u8nkZph6UHC4B703aw0So5PXp607fimIvrSiosih+7jmkLkGk6ijAxzStYYjSexphfNOGO9IQD04qGUhFNSbhjFRAYqQCnZdg+YoIz0pflbqAfwpAuaOneqUV2DXuNKIB9xP++RSFIv+eUefUoKc2ApZiAoGSTwKEKsm9GDL6g5FT7OC+yvuBSfcDx0Ax6UnBpwGeaaaqLsDEApCKXjFJjmkAqjmpDwMU0AU447UhoABTSBvHqBTs+vWmjljxTQNiNRgUre9HbmqRA3tQQMUoHNBxjmk2NCRqADinbRjjrShSPpSkZrRbEtDAoxTHA9KlAphBzVolkLqvNMKjHSpG600jiqJY3aMe9BUE/SndulCjmhbiewoUelNKDPQYqT600da26EDVUZPFMIA6VKRgHNRt1pITE2j0opaKkLMaijvUwANRI3GKmU5FQAqlSSMjI7U7tQMD60pNFi0MPBpCfypc0h5GKizeowXn6VHLcww482RUB6bjisO98X6RaXktq0ssssZKv5UeQGBwVyccisq61W11OdiPkXoM8HFdEcNPdqyK5WaGq+JQreTpuHbkNMy8D/dHf6nj654q23iC+RwZJFlUdQygZ/KqLw20ZJjkEnvVKe4jUHDCumnQha1jWMUdc3iaFQMwOW7gPxVCXxVL5m1FiUf7p4rj5r0Lwn61WS5BPBGa6IYGG9i1R0O2HieZZQTscdxjGa6PSNSt9UiLRZWVPvxk8j39x715hG4PJra0KSWC/huo/lRDz6Mvcf59qzr4OHL7ujE6asekDj6Ud6YjB1VlOVIBB9RUF7f21nZtdTSp5QHy4YHefRfU8V5iptuyRldFpmA5PApPMTH3ua4aHxb511KdRTyYsbo/L5AGehzj86xbjxpdTs6wokEBPAOS2Pcg10rL6j0saKEn0O51PxRoumuY7m/Uyg4KRK0hB9DgYB+uKqW/jXRpWAWWUKf4ymQPqASfbpXjepzSXMzFCfnOSx61kQXU8FxGIMuSeExnJ9hXdDKaTjZt3OuOFur3Ppm3ube5Gba4hmz/wA85A38qsYYdQfevnuG7vVVXvUaJHJ2grtz/nNWjqM7W0du88z26Z2xFzsX6L0Hf86yeU66S/AzeHkup7Re6/p1jNHFPcKZHbHychfcnoOn19qTUNbsbSJT5ySyOMpHG2S3ufQf55rya1uDNGocZI4HerVxcpb4ZxmQ9ADz9T7U/wCzoKyuSqPQ6261Ga5+e5l4P3Y1OFH4f1NVPtctsDLFcSRcjkEjOOmfWsCK4vLtD9kgd3GAdq7tuemf8a0NM0PV7u2V9S2wv0AJBJH0HT8cf1q3RhD4miuVR3Ojt/E1zFb75US4H/fJP4jj9K6HTr6HUbRbi2bKHgg8FT3BHrXCtps8SiLyysa9ST29ataVqtvpDuiuHVvvgnGcZxz+Nc9TCxkr01qZyjde6dt1PPSnDHNcvP430yMfuEuZn9NoUD6kn+QNVx45jJx/Z7f9/v8A7GsFgqzXwk8k30OwzQW+YHtXMxeMLOVB/otyrdwdpH55/pV+08R6bcYDz/Z3zjEgwPz6fnis5YapHeIuVrc2c5OaXOKRCrxh0ZWQjIZTkH6GkxWPKTcU5PNJnmg/pTc881SiK48c0tNyPWlJAFLlC45TmjOKQcdKDxVcori5pjHmlJGKY3FCiyWxh9aaBnNLnNO4ppCGKCDzS4+ancYpRQtwewd6QjFOpK1TZDQxmzUR4NSn7361A5+Y0LQTH5HrRUWT6/pRU8w7DkPSpVxxUK9eKlFQBIP0pcnOKRad2oTHYQjAzTVJDjPQEZpTmkJwKTQHhGqWkmn6reW8ow8UzL9Rng/QjBp8V2wClWIIrtPiFo7TXovEHMiD5/8AaXjH5YrgZY2jXJ4FfR0ZxrQTe56FOXOrmyNWiZQrMUbue1RXN0hXKSqw9mBrDYrnk1XLDkA1rCgjRRXQ13mJOQc1LbRPNIMMAPU1jQtkkBsH2q9al8bS/HYE1ryWQNaHVWcUUZVnG7HrWqt0uOAQfeuWsY5LiZI4C0kxO1VTkkmvQtB8PtYhbvVZ4meMZEa8qvpuY9T/AF7mvOxEoU9ZPU55NRWpwHizxjcac6WIeZUdd/y42npwf8+lc3dajf3u2dJZBEh3KEGAM4546/56V33j7QrTxMRdWqA3US4XkrvHv6HH9M+1bwH4Zu5bgG4tngsYzhmcbSSB91QevXr0685ooVIwi5v7upuqlJU00tepXsr9LmxVzG2TwwxkA49PTmufvrO4S4Z45VWGQkgLkFfavYZ9N8PaRZsbmGytbd2yXlfb83sSePoK83utQ0KTW41Sa6m0tZRvfBBZe4HAOOgzweuOxq6FbnbcIu39fiZUp3b5Voc/sS1j/fyAjP1ODV+wtrGC2W+smNzdFvlDKdiHjII9f8a6nxPrPh6+8OyaVplpgsv7o+Vs8sjB3A9SxwM5POec1yfhXT7yd5LZY5EyQQ0nCjqM59OnNaRnKdNya5fXsbqbkry0KUFvd3lypnZpJWO0dOfYDtXVaX4YlkZHmRhHnO5sD9Oprd0zTtN8O38dpNMl3qk2MiMglTjO0A9M+/XHau1+zxMNsqhhnPUj9a5a+Ma0itGZ1MS/snN2Xh7T1th5aI05B2s2cDPt0rBPgrUZtQae5kghiLYPOc8cEAdvrivRvLtreIykxxRIPmdmwFHuTXB674qlvrt4bAFLGPhSwIaU/wB4+g9B+J9Blh5Vpt8r+8yp1Jt6M6HRpdO02CK18yKPGTk8Fj6knGT/APq4xUmpeJbG1YrAjXMn+ydq/mf8K86R3u7qQyN8/YH+lJJIVby0OXzjjt7Vt9Qi5XbuX7FPVm3qWrXV9KWfy0XsiDA/E9z71grDLcO248k9MVbt7adYN8w2k8hTUHmbGweMntXVCKirRLT5VoVZ4TDIQWBx1Iotw0j8dAOTSXKtIQF6VBfwagLHbZAjkFj0JHoCeK2S03HKdkXjdLFwCMDqar/2rEJNgbL9wa5S/XVAVWRrpcnAG4gH6Y4NXdO0426CWfmYj14X29z7/wD66PZRS3M02zr9K1uazkJsLl4XPJT+Fvqp4Nd54f8AFdvqBFvfbLa7LYXrskz6E9D7E9xjPbxti6yhlPA9614pQ6gEc9xXNWwkKi137g0p6M9xYEU3P515/wCF/E0tkEtL9jJZjhJDy8Q9PdfbqPpgV3qsGUMhDKwBBByCPUHvXlVcO6TtI5pxcXZjx70uKaOTzSlvzrDl7k3F6dKazEDijPrQeafKITO4UnTOaXpSE5PShRE2IOtLRig5pxQmAPBpQabu9RSZOeKnZjJB60FuKYhGKRsHpV9CWNYkfWoSc9eKmOM/SomOelCRLG5opaKVkAIc/WpkBNQ55zUsbc+lZcoXJgcUhNIKD0oSKuITSE0pHGab9aLBcrX9ol/Zy28uAHBCtjOw44NcB4MtHt9dvLHV7XcfKKski7k3D17EFScetejDP0qC4wTuwC2MZxzj0rohWcISh0Y1UsnHucVrPgOwnZn06eWzY/8ALNv3kf4ZO4fmfpXMyfD/AFpZAEazlU/xLMQB+BAP6V6gxbPTpWFfeKobC5a3mtZ/NU4IJAyPXrXTQxWJ+GDv6mkK9TZanO23w3veGlvrUAdQm4n8MgVYh8BTvORLcrHCpwWHJb6DH6/zrtNN1L7dEGSJoyRnDcmpXt7+SQlHhjQdATyf0NNY2vdqUrD+sVNrlHRdC0vw5DJcqztKQR5s75OPQDgZ69BmhbldVZ8bjGDwCCKrjw1cXOotdanfGWMfcjQkkewJ4UewFdDaWkNsirBGqqAPespzje9+aRDl1buzP03TNkrM4xGO3rW5lVUAYAHQUqgYpCAeawk3LViv0PIfiNaX1ze/anJa3XKInZMHqPr+f9MjTtJWS1WQpuL88c45x1r1fxlaLqGltbIhadh1B6Ac8+vSuT8M6ZeWN2I2sZJnx03bAOvOD7jv/hXq0cT+57WOunWfJbsZFnp8MN9DHNhBuHy9SQc9ua6HUl1ENHaaFp8x3KD9o27VXrkAnCj6k9/XFdJYaBbpdLd3saT3nY7fkT/dB/rUOreLrCzZoYSbiUcEjhFPue/4fnWKryqy92NyHVu9FcwrKyh8NS/atQ8qW+kJ/eqScA9SMjPPPPt9abq3jEkrHpylTu5dl3dOwH+PpXJeJPED3948khAJPCLk7R2HtWVFeSHOF57E13QwvNadTVm0aTfvS3OnZ7vVHze3M0scfzBGckAn0HQd+arXRWOXbHx0qlb3F4M9EzxyOv4VAzu1yVllHXBNbqnZ6bFKyZdlnUZDdcVJpdzbWszTMgaTqPb6elUPs8BJJmA9hipoYrdV4bJ+tU1pYrmi1a5o3mrS3MheX7o6KvYf1rGuLyR5MgADPSrKNCWKnj3Jo+xRzE7JFB/OnGMYrYi0R9vOZF4xu+tVdT1e7s4GIRGTgfd/rT5tPuokJjYMB/dPNUxduCVflgec8UowT1WopQ5tUU7bWb69jZJYY1RiOVBXP5mp5JZcrEzBVyMkdR+NXYbyDaftAK89cZrJ1K4LFvs3LHIBYYANUld2tYi1mXI47GMEXGp26Mv8EkyLn8Cc1Os0cZOHU46AHNefpaXJkdZ0YNkkknOffNdFpFtLK6RIHY/0q5U1vctQk9Tr7O48yInGDnANd78P79mt5tPlYkx/vYc9lJ+YfgcH/gR9K4KG2MMYDHGBzzXUeCoGm1lJVYBYEZ298gqAPz/SuDFRjKm7kVbcp6EOOaQnvTdxoZuK8Y47jx0zR1qNWo3DikIkpD9aYSSOKAcimkDY+mg4ODRmhj3p2FcG56cU3BB4pC/HSlDetQ7DFUetNbilz6dKa/zdO1FtAuNJJzSE0E0zPNCJYcetFJkelFIBQ3GacrZqAHj3p6HA61OhBYDYPWnZA71B+NODdAc+9FilsSscjrTAxHWsyLVC52zQtA2SuGYHvirM91BbxeZdTwwR5xvlcIM+mTT5LOwua+xl+JvFOn6Dsju5d1y4DLAnL7fXHboeuBwaz7Tx1oNzbpJNeNbOcgxSQuWGPdVIP59+3SvKvGk4ufEl/fWskkttcSlkeRcHoAB64wOM9selY80gNuZfu7BzXsRy6k6abvf+tDshh4uN76n0Lp1/ZarB9o026iuYh94oeVPoynlT9QKsmISECRQwHTcAcfnXzr4W1XUBqkf9ltKkxBBMTEELkZzjqM44PXjvivbrX7fPd+XHe5Cn58scAfh+FceIwaovR6GNWk6btc6iPCKFUAD0AxT93NVYYzFEoaQyMByxHWnh/wC8Rn0zXGkjG5N1+tZEfiGyuZZEsp0m8ttpZTkZ9vX/ADiq3jC31PUNFltdFkWO4lwrOxx8ueRn3GareD/CUOhwStcyi6upmDM3IRAOgA79TyfwA79EYU1Dmk9ei/zLVnG7ZbtbrV7rWITEirp4B8wsB/Prn6cf16POKhQ7OAAB6Uu+pk79LBcmCrnOBk9TindOBUQcBCWICgZJJ4A965DxH4rCq8VhvVeR5nQt9PQe/WinRlUdolRTk7IXx3rnkwGztJQinieQHr/sA/z9enrnzO6Mt+yrApVAeXJ6irN473TGW6YY7DPAqv8AblVNkCgAcV7mHoKlGy3OuLVNWW4+OxtbdQZAGbrluTmn+fGMeVGBjvjFUfN3MWYkmmtLtJIHFdPs+43Ub3Ls05mT73HTFU5G2jdnpUcUhJIfAHY9M1ZtrK4vpGt7RQ0zAkbjgfX2qmkokrUhExY9/XFKJnQnAPFBsb7TZPs+oKPOweQQQVycHj6VFdSi1nVJnG9hnAoi09U7mnJbUbE8zzMcHB7VdRZTjCmt2y0K9urRJ7O3mmjZVcMFABBGRjnnqOlLPouow8NYXQ9/JYj8xUe3g9E0S+Xa42yaRYlE7ZP1rI114mvgIyDJtG/Hr2/StJtJ1aTP+g35XsRA5H8qzLvTrywWSS4sLlAoyWeB1/mKiDje9yoOMHe5UlCLFl/wqhcXgVQMAfWmNdC5cYcYJyDngU2XT3uonMZ3IOrJzj61ttuRKVytHMJrjY5xk4HFdHpd1FYRyFY97MOMH/PFcVHbTxahsZjwwJOeMetdJaNsk+YZVlpSS2Eql04s1odQlnn33L/Ln7qjAFdh4auVgvFntm3KOGXP3h6V5y0nlSsG6djWlpGom2uVMUqgggjnIz6H2rGrR5lZE9LM95BBGaCcnrWVoOrRatZCWPCTJhZoc8oe34HGQfqOoNaXIwQa+enFwbT3RzO60Y8n0pQB3poOaCTkDNKzaJHZ28d6CcZ5zUZOTQTQhDgSO9Bkx14FMBxjPNI+CMVSAkBBFJUfIpQ2D71n1KuSbiDSsaYDkU0mnsIazMG9qTIIpCTzmm4600Sx+G/yKKj3t60U7INRB9KkHIqJWx6VKGz6ZrBJhdD1BrO1PV7XTGQXZdQ+SNq54HWtAttzjmvJ/FWorf69eqrgop8rhjgADBH55/M10Yag6s+VlQ5ZOxH4q1karrsdzav5dtHhIcjBOOrEep/kAO1buhLZ6vFs1i8by0i/do0hUBf4j7dB+deZ32ly2c7RyyGVByMn5sEZwff/APXUz3E96VxkIg+VR/jXsPDXio03ZLqdkoRlFcrsXb23SKaRI2MsGTtZupX396z7u3QWbKuMdSMf59KFvHLiJsluRWvY2UWossQDqD94MPStpKUFdjVVR3ND4UWHn/bEgzEMLukAzx8wx+Z716VoWiW2h280diZnMr+YxlbJz6DAHH6+9ReF9Ft9GszHbooZ+Wx3rczzXiYitKrOTjszjq1lOTaFXpzwaaIk3bnyT27YpxbjNIGDD3rnUJGXMiQADpSjpzxTBwPel3Hjiq5ZFKSHAcg02RsED1pd2B2Fch4q8Rxw/urU5boCOp9/YVpSoVKsuVIuPvOyJfF+vJCjWVuweQ/6wqentn/P864C4uGZizklvc0+YvsMr8s1Zpk+Ylua9uhh/Zxsje8YaIWeQlTnNZjyCNz2B6VcZvNcgD8KJLMMPnXg11xTSKi03oQxgyH5alk2onzGux8I+EkvbeO4u962pyeDjfz27/j0/lWD8Rre1PiUabZQraQxIgYKcbycsW+nOPw96yjXU6ns4lKpC9lqzEOoWsW7zoZZMDPyqP6mse28V32o6hJEiHTYuf3cMrBhg/dZuCxBY9eccVZdAkpUKNwPNY120dxrUQTqWVCyjk+v+fauuNJSvzIpy5nqjTublmLF5WkcnLb2LEn3qq8qqpZ5MMQSqmNhn6HGKlsoTbTRC4Ty3kYkE45wK1baKa4mRfNby13AqABuzjH6Zo+FkuUVodL8LPGX9mr/AGVqBY2zHdHl8+Wx6hR6Hrjuckck7u+1/wAWxaXd28cCQzIQC5L4Jyccc9uueevbv4Be3j6dqxltGBkgYYbOQSM5H64P40uqi+uU/tC4uI2unUERHOcf3QP6Vy1cuhVqe02v+ZEoRbutmfTuk6rZ6xbtNYS71Rtjg8FG9D/j7VeUsv3SR9DXgPgrxLPoUqDZErqSpT5gjqeSPUc9K9RsvHmnSRbtQQ2akhdyt5ign1wM/kD615GIwFWD91XRi7RZrah4b0TUZXlvNIsnndt7TLH5cjH1Lrhj+dVW8IaIqlIrMKPd2Yj8Sc1vxOkkayRurxuAyupBVgRkEEdQRQcFs1yKdWKspP7w5zzjWfhojyNLp90ccsscozgnsD1A9+f8eD1i1u9NVre5t3ikiPKke2eK+hGORVPUbG21G0a2vIxJE3Q90Pqp7H/JzXXRxlSL/eK6CNRI+d5A2p6Vuj3LMnpwSB/n86oWUnlMoYkj1rvdd0aTQr94Z1HltlopgMLKvr7EZwR2+hBPG6zZ+TcefCo8lzzjop/wr2qU+ZabM35k0dNoGs3FndRS20oSZOATyHXurDuDjp9MYIBr0qy8SidUkaILGfvLuyV/z+vtXh0M2MHOCPTtXU6PqnmoBuxIo5965sVhFP3rEtxejPa4XWWMOhyD604iue8L6tHdxiPcBJjBU+vr+NdCc14c6c4PlZztpOzExQAc0pPNIWHY1CjIXMhJSEGWNCDGdx59KUEdetJn6VSjITkgIycUY+YUZpwxUOMrj5kAGD1pxAxTWb0qME85IocZD5kDcdKj29TTi+DSbgaajKxLkg2Cik3D+8KKXLPsHMiBelSpwetRx84qVR+NZq/cQk8RmhkiLsnmIU3KcMuRjIPqO1efTfDuSyAfT7kXRVfuyARkfQcg/if8a9DVuRUnStadepS+B7mkJuOx5nB4CvboF7y5is/9kL5h/HBA/WtnRvAen2RJup5Lw9du3yl79QCT+v512DEU33rSWLrTVubT+vn+JTrTelzOu9F066txDJZW6hfulI1Ur9MCq9n4ft7PBgO3HYLj+VbPQ0hPSslOaVkzJyZU2XUTr5exou+etE32wrvVguB9zA5q0xJNOw237uV9e1JSZJn2epC+WURIwMbbWyOh61dt4ygPzZJOTntSoAnAAH4U9T34p3b2AkXAHNKpzUZOVrE8TayNOszDCxF1IMAqeY19fqe35+mapwlOXLEtK7sit4s14W6SWlsckfK7ep/uj29f854RmLFp5zljzUN5cHcGkJPYD0qIXKv8rcgjFe7Ro+zjZHXFKCstyOeWaWQHHyeg7Uv2feOc5qxaoqEY5B6Zqe7aGytQd2ZWGfm7Ctm2tEEddyqtsI8YGXI+taNta2tm8M+uSB4pPmS0i+Z3AxyxBwo7cnJ9O4ravBd6Noi6pfW7xxysEiD4BYnOARnI6ZwewJrDs7lyDNOWZ5BnJPQf59KlJ1FdS08hSl0id1d/EQRhYLXS44I0AUDzd21R0AAVQOOPyrifEN3LrOuNqEgSLCLGiR56DPJPc8n9PrWbJO8t05k654+lVJXuxK7K7eV9eAK0pYaFJ3joEYpaomaNVnPmE4J71UjEVvctJEu0sc5Cjj17dKjhZXucyTRozsAA55J9hS30TNCBuKA56cZ9K60ru1y+ZdSOdDf3JkdpNyrhMNgD3qPWJNQSH7Oko8uUDJPBI6Ebv59/zNT2M1vBIsLb/NOAC4zk/hUWvb5bR+RkEFQR+dNXUkiy5pUENqqO4SaUDgnGFPsKZPC00yTNKV2Nnr6VjaHJuuVBUs5B7gf/AK62vtcDr+7dG2nkelOScXoxSbJlmEmMgZGccU1pEl2pdY+Q7kJyMEd6qujySRyQFhzkgHg0t5EWYKw6n1rJqxm1Y90+GuvW2oaJHYK3+k2a7XAQhSpJKnPc9a7NSD0rxb4VeMfD2j6SbC8inhvXkLPdhA6uv8IJzlcZPAGO+ck16RpvizQr+YR2+oxh2+6JVMefxPH54r57FYepGrJxi7GEtGdCTimHJNB3KSGByO1NJJri1vuK6sZXifRIvEGlPaOwjnRt8Ex/gf39iOD19cZAry99JkWOW1uY2V0JR0ccg/5717JnrXJeNrUoiX8aZ2/LMQO38JP8s/Su7CV5QfJfT9Soyszx65sntpmRzwOh9RUdvMYJgUOGHvW94gi+027tAQJMEqff0rjbSYBijn5ieM17abkrtmr0PRbK4ZVjuIWKOOQQeQa9Y064aezilcguy5JHQ+9eJaFMz2hBzhWxmvQvCniGBhBp9wwSTAjQnoSBgDPT/P5+XjKUmrroRV1SZ2ufekPAqLJPHTFODDFeYr9zC4oPNKc9aRefpSn0zT17iuKDmk75FBPGO9Ip9ah69Sh4y2cUhUj3pQQKQsSaWo7kbDrTScninsD9aiJqlfuQ2L81FM3miiz7sAUYHFPU0wHinCsUSOHJp+cio84NKc9RzQWhTyc01nA4HWk3UnemiWLmlJzTeBRnAJJAUDJJOAB6mquIh1C9h06ymu7okQxDJ28lj0AHuTgfjXk11rupXerC/luHSZCTEisdkQ/uqDxjHX171v61eXHiPUjDZrJLaQn90iqcHt5je57Z6Dj1zy2q2rWrgc4P4Yr1sHRjDSe7/qx0Uopb7nqN/wCIbez0BdSXDtIimGJjgszdAfoMk/Q81c0Oa4uNItJ7v/XzIJCBxweV6eowfx7dK858KSLcTWtpcoskPmqNpGQQXzg+vU16B4g1UabaeZuBnkOEzz9W965atBQkqUVd33MpQ5fd6jta1620qNlb95ckZWMds9Nx7V5lquoTXdw887lpHOfpUOpXcskjSOxZ2yfmOST6msfzHbJY5Y969LDYVUl5mytDbctSy7wc9RUUbFjheTVdBJIcLknNdL4Y0GfU5WSLARBmWU9F9APeuqco043ZS11ZSiynHU103gTQmvdWk1PUAWt7fHlIwyJJPX6KO3qR6c2b7TdH8K2pv9cvvvgrDEBlnI6hFHLHkc9Bnkgc1zk/xQuYLFk0rR7dXCYiMspYKfUoFGfpkVyzlUxEGqK0el9hObkrQM74zazean4vOiIZFtbAR4jD8SyuiuZCOOQrhRnOMEjG41hWMd9Zp9nvo0WNV+Vy4OB0xkGqPmX2s6/LqupyossswmkfbtBxjCqvoAAOfTkk9dvUpjdJtUjy88Y713U4qnTjT00WvqXayUSlcLsYtuUqeQQazylxfXboZkjs48YCZ3ufeq80X2edmRicnnPTNWLdDGfv5JJJwOK6EuVGltBsvhs3JXyLpFkAOA0fU/UH+lBsbqxWOK6Yzx5ChlJIX8+QP0qxJdIhKFmD44IJGD9alW7Lgh+QT0Ipc0+orvqUmtjHslGMg5wPbpioph9oVHlGcDpmm3811p8/mKVntZGyo9PUe3157Vm3mpyXShIoxCO/zbj/ACFVFNtMvcnktjEN6JvAOcHk1dsLa3S083yyJn+9nPGO2Ky0vJY08l8h/U9SK0rBpTGPNyQeRzmrlewNsllvTp8azGLzV3AbCdue/Xt0rTvJ4ZYILuxJaCVc8jBU9wfQjpj+dZc0sU0M1rKpCyLtDH+E9QfzANZ+j3Emn37W03MUp2OmeN3Zh+g+n0FZqHMvMXLfc0dO07MpcKpjHb+gqePUQWYAbcEjBFWRMts2HbarHAPvjimSWsc43HqeQw71F77ktXepqxeJ9ct7WMnVL+K3iA2FZ3AUdBwD/kV2uh/Em4huo7bxBCkkBIVrqNNsi5ydzIOGHThQDjnk8HzAbmBs7xN8DjaSOO/FVLDTZbW/ECzAQkHYx798exrnqYajUXvIh011PqbcrqrIysjAMrKcqwPQg9wfWmuqOrJKiSRt1R13BvqDXC+BPFAlWHRrvPmoMQOT95M8L16jJAHZQPSu3YOFLYO31r52rTdKXLI5vI8p1/Sv7L1W5tOfs5/eQ85/dsTjrzkYI57iufOjWbu0rxZmz1yR+ma9Y8W6d/aOltIoJuLYGSP3H8S/kMj3A9TXmjTHYTGMtjj39K9bDVnUhfr1OiEueNixZwLb2p+UBc1bt4YYmguDwVdXLHnoc/0rCtb+4usJcxiIqeQDwa2bqb/RUiVghHAYH2rScbaDlBxjZnqsL5gQ5zkdfWpE5zmvM/h7P4rXXI7S4aK48OBH3u2wtEdp27Tw/wB7auORj6ZHpinBrxqtP2cuW9zk8iYDjinYpEIIpTwPas0AdaaeOtJ1FITUFCr160/imA0oPNACE4PNRHGTUr1CetUnYlhmijiipuOw1eRmlUkk0wMOlPHI4qEyLDqepIFMXIPvTs5FD7lIax4FMOR3p7YA965rxh4mj0S3WK3KS6lKPkQ8iIf32H8h3+gq6VOVSSjFahZt2Rqarq1lpMYN9OEcjKxL8zt9F/qcCuSOs3/i2+bTtPjFpYLh5pG+ZtnYt9eyjv3wCRwlzcyPLJNcSPLPIcvI53Mx9zXqfgix+w+HLYlNslz/AKQ5znO77v8A46F/WvRnQjhafNvL8vkW4qCu9zZsbKDT7VYLRNsY6kn5mPqT6/8A6hgcVxXxEsWSeO6AHlzAg+0g6/TIx+Rruyx21y3xDKNoCBmCuJwyDPX5Wz/P+Vc+Fm1VT7kQfvXOA0i6ktb2GRequGAxnoc1v61qh1K8EjAKqqFUfn/ia5a1ZluN2QQOxrr9D0y31mC4SO4EdzE33cZO098envnj8a9Wq4xftJHTUslzHIT3AklY7uOgBqEBi2UBOa6LVfCN5avuMfmDP/LM5/Stnw54QmfZNqsbQQdRBnDvxn5sfdHPT73Xp1q/rVOEea5ndWuzP8H+HJdVcyyborJSQ0o6uf7q/wBT2+vFen2dtBZ2yW9rEsUKdFH8ye596fGqIiJGqpGgCqqjAUegHYU9unHFeVVxEq7u9uxnOfN6HlHxctY4detr7UpR9llhEduZDhUIwGXr64b0+f6151qQkjOIFwB6V3n7R6pPpHh22Mcjk3Ur7l6KNqrj6knjjsfbPCAGK1jVCQFQDnJx+Jr28F/AjJ/1Z2Nqa0TK8V3KB5cy4OM5XgUkUe6WUQyMpblwG68d6Edi5HzM3PTmk3bWJCFZCOcriuyKubDoJhDMY5kO3pz0q1cSrAm5Bu/GqU1xvXDHGO9TJNG8eAAdvBzVNa3H5kW1pnL8KT6dqAtwkwO4BCefTFTX9xE1v1KOPemfaUaEbJQ5x2NPW2w0yPUY5jCCjNIBnKjjFV7a1RbdZzkS85UjOKswksx3Hj3pjyxtuRWHrnBpq+xRXllNzbrvRQRkK2KkjW4W3UxOD6jbyRU0FuohjQncQOo96iP2uG7VV/1S4xwDmh9hD7VWBLMsiuDxlcgn0OatX1raeIoWfTZE+1xj5lYbcr6MPY9D/wDWqtJJI+owSguqIclQTjAzk/kTUVpci38VxXFufvygNnuHGGz+Jz+AqXffqDZK1yL1TZ6gPs+pwNjDjbvOPyGR+B4I4OAx9OmRkKsituGOeRWt4rtlv7b7ZDsE9rGWfDDJjHJ5/wBnk9fXqSKw4tZ3xiK52Z4xIDjp0z2/lURu43iC12Jbhr8XAjlVnQEYccg/j/jU811MbqFUdmfzcD154qC5vWMR2BXY453YxV/SlCyJPICSQTjPOai/dBbQ6eV0ju0ePIZDlWHBFVV1jW4b2S+W/vGvR8qtLcFsKTnbzkbeemMVmT7ppyV6tg9a04Gt9PtC00kSE43u0gCg9Op6VjKKt3MJrQ9Q+GWvaprmiST61DHFdQzbI5ETb5yBR85Geu7dkjAPGAK5Txfpw0TWTHGhFnOPNtyAcAZ5T6qe3PBUnrXJaf4kn+0mbSNQljKndtjYr+JU9fy9q7G68RJ4j0O3h1CALqNvLuMgT5XUgjI/uknGR0+UEeg4XQnRquSWj3XYhXhIxgVdPMB5B/OnXEwlihVc5UYJpZAojCoOPap4IoltGZvmfsK6G1Y2k/dOz+Hlwx02aKT+F8oT3Hf/AD7+1depzivMfCl99mlVWJCbwPpng16cgKqNw5714+Jhyzb7nLIkBweKduNRgDsaFbBOawRA49KTdjrSnmkIHOagrUcDnmgnniozIkSM8jBEHVicAfjQkqTKGidWX1U5FPbUBWY00+tKw9KjY8jsKehLHZFFG1fX9aKm67DIsE4qVOlRKeam3YHPSs0SP7UpNMDUp6UhozPEuo/2Xo1zd/ekQYRSMgseBn29a8VnllnmknnZpJpG3MzdSa734j6gZZFsUJ2QYkk92IyB+CnP/Aj6VwLuCpwK9rAU1CnzPdnTSjaN2aXh61jvdcsIpkDRtMu5cZyBzg+1exgknnqa8f8AD12bS7iuFUF4mzg+leqW2oQ3FqtwrARFd25jgADrk9sYP5Vjj1LmT6GNZalt2CIzOQqAZJPYDrXlni7VpNT1Bxki2j+WJPQHv9T/AIVu6/4iN4jwWgZLbPLngyD6dh+v06VweoyZnfk7c1rg6Dg+aS1KpQ1uyKKQwSjLcZ71uaJqf2HWYLuJiv8ADIFGdyHhhjv6j3ArliZZrqKNDkswUZ96u3Qms7jZInTqRXfKCno+p1yhdWfU9xRvNEcylXVgGVl6EdiKuRjC4rzHwj4h2zG3DIkZG8hzgEg8498fTOPat1viHpNpqD2upg28YJCTqd4YAgZ2gcDnPUn2rx54apGVoq5wSg4OzO0FKQAMkgAckk4ApkUsckaSRsrxuoZGU5DA8gj2rhvi74rm0HSILKwEZvNQDoWcE+XEMBiBjBJzt5PGTwe0UaUq01CO7ElzOyMj4ka3azWqFVV5DIVjy3JA68enQ/lXkUryy3o6kk/lV22mlvpY2nlLy5O5nJPGc8f4VHqStBcgW+GPbAyelfSUKKoR5Dppx5XYltLNkuBIDnA9fWkglead1niEcg77tw61nCbUkk2nzSCRwF4/T+Vakbjyg20LKDyPetUupq9NSu6ASYIIfuVHH500xkTGRVH4GjzvMn2yNtc8DJ60yKcx6gIZOQzBfxP/AOursx37leRhcyyICNwOOTiq0OYb2NJeAXAPOO9XryKO01AzIvLYbk9//wBYqBoftO+VFAUHJ5rWLuijXYBc5C492qKU2vlbUX5v71NtbbCfNtK/Ss6S4YX20RkRBgMY6is4rWwLY0Cfs1nJPkHZzg9PQfrUVrfzXCiR40xkj5c81BrFq91DD9mcHYSxQtjPoeT1HP51VsJ7m3URbFdSclMdfxFW0rXBnQrvBDYIG3JrE8uQ655qBjGGDDj24/WtTzJNrZxtI/v8j8KrwCVblXQ/ICM5PGKzWzYklujV0zxBL4f1221CLYGicfLJ0I7965rX9ENvfSTaQoksHYssUbEmIHkKCxJYDOAck8c+tXNbWHdE93JtUH7p7ikttSF7beVboypD8m0n7o7fyrOOnvpf10KWmqMrTbuNLlAXUZPCt65rfnnuvtMIgVHWSTZjDEjjPIHTv+ArPk0yz1B83IcS44ZGwf5Vt6SI9PCRLI3kqoQADk4GBk4pTl1SCTW5lTabr0t39pivkijzwFdlwPTAXHbp+dT39nPdoq3EwGGzk8/561Xv5J7PWBM087W5kB+91XuCOnatDULywnt1Zb6IMvbeP8/jRzO6/wAiE9jMCHSgJUkjkmIwvPQd6mtvEkwuMOscZKtyCcE9QMc+lGkXUGpSSpuUpAPMIkwOP73Pb37ce1dB8G/D8Hi3x1e3clvFJpmmJvZHUFZJJAyRgg9OjvkDgoOhOaivVjCEpzWkf6QScdXLob0W9B+8HYH9KSW5xjb+VC3InubtFULEsjKigYwu44H5AVJbWq7hIWyM9K5envCtdWNexSKONc/ebr/9evVI5PNQSAcMM15CJkUl8j3xXrFjG0NlbxSffSNVbHPOOa8zGJLlZjWjaxY7UDinDpScA1xmAE4+tQXd3BaW7zXD7UUdOpPsB3NWByemTXH+ItRjOqmBHV0iIBA55xzz606UOeVioxcnZGRrF5carc+dKxWNT+7iz8qD+p9T3+mANPwdK66iYELbGQs2Bxj1PpziqqumVAX5ScccV2Wm6fDYIfKQeaw+dz1Pt9K6q1RRp8ljeclGPKW/WmtgipMZFRsMVxXOZoZt96KWip0C5XU4PvU2SRyKgjCnmplPT0qETdDlJLY7VJnJ9qZ75odsDNA7o8l8RbhfakJOJDPIWHuXJrnUbJ24/Ku4+KVlJGLbU4F+SRhDPjswHyN+IBXPsvrXBxOcg559K9/DTU6akjtg4uCZbhcwSZ7Ec1tWd032d4fMbynOSm44J9cfgK4vVRe3BVYSETuSSKv2Fy0cCxO5ZlGNx4zXROF1cmyaNu6lO4hR0rCuHBYZPP1rS+0h4TuHNZUzBsnFOnFjjZDY5/IuIpgNxjYNj1welaviS7Tz4btG8yG4XduHr/TiuflYspHeo4me6gS2YlghYopPTucVpKG0uxs4Kcb32NGN8kyQnAPUCsnxU5kszKWHyHdktgZyP8KbaXotplX7yt2z2qS92XMEiGMPGckITkHuKq3K7mcfeXvbo9p+E1w1z8N9CkfcWKTDkkkATyBRk9tuMe2K4T4uajb6r4uj08AhdNj8lpQQQzth2HXoMqv1DV2fwauFl8EKoAEcFzJAi/3VCocfmxrz/wATW3l+KdZW6UCY3UrMT3VnLA/QhgfxrzsKl9am30v+LORNKVzh3uPs8oaNuhwDir81ySodDnPtWdfALeyiGJzArZDMMj8/TOcUTakS2xolIC444z+le5bn2R16bluK4ZiWT5vrSCUzg4G2QH1xzWcshBDRnBJ6Zqwq7QHJAbuaOWzCyQ+7hkuAp+XcPbrWfcCVpYmgGZAdylfX1/OrKXUguAhbg9Kkkkitx50hUfw4A5NUm07FJpGpepDcPHvGcHt1x6Z9Ki1Rkhsh5SqqscYAxj8KpWuqQ3bNEgZJlGVD4G76c/pUlvM+90kyVIwQwzU2aVgduhLpF158Tw4JK8jnHX/Jqu1zcefskgG4N91etVluVt42eAlGXPapLK8N0MuAHUdcdarkd+YaSRaiaRpVSVCHbu1MnspFu1keQFCM8fKQc1asIn1C8S2iClz3JwAPetXWNKtbbywzs0idOTk/5zUudny9SdLnP3OnTzKjJJ8o5w9Rat9stbLZpskf2hiBlhkqO5GeM9K1ju2HaSQKpXdncTx7rdgCPXgVN2/iNFZbmBFpU87GS8mKuRksTuZj71v29stjpWIRleTkdS3TJqoheWRonB3p1qS7uxawFT820Yxnrmp1Ym00MjZtwYHB61dgunR/9JOyEL98DOD71g2080socNhT27flWnNYTXkQV5dqjnAPf3okktyHbYNUhbVmRbNC64xGzKQefY4610XhD4T32p2bXGtXQskI+UIwOBnrnBGe+OeCOlYFvK2jQDK73yCg3AYPXPfirF14g1jVbEQz6rdR2yH5LZJiqL+AIz+I459axmqrVqbsu5LlaPusua94b0Hw495HFfzS3ADIokdWYjGQMKoxnj07V6D8EIbDTvA+patYOrTsTJekOSYliDFEKjoAu5vU7zycADxH7K11vgg3GQnYo9z0wBz1rt9A0e40HT5NIaZ3811nuFZNoWTauVAyc42jk9+wrHFUuan7OUnv+QpK9k3e5pafG0Vl8ud2P5CrenibySPmIJrY0nT5LgRxW0RkY8BV/r6D3P4132ieH4bL95dFJrjp6qn0z1Pv/wDXzyVsSoaMmVVRlc5fwloj3N+kk6HyYSJGyOCR0X356+2a9FGRwaYiLGMIqqPQCpCR3ryqlWVV3kYzqc7uxSaoalqkOnxhpPmkYHZGDy3+A9/51Jqt6LDTprll3bANqk/eJ6D/AD6V5vcXc00rTTsXkY5JP+f0rWhRdTV7DpwUmbd9r95ell3+RFk4jj44926n9B7VgoCtyTjjHFQiVy2Rn61oWUTXM0UZwC7AZ+tdqiqa0OhqMVoa2hWT39yqkMIV5dh2Hp+NdwMnpgAdgOBVewtorS3WKFQqj9frVrdXl1Zuo79DnlNSEJI4qMnIOac5G01GOOtRqZtoXj3opdw9P1orPQd13KS9cVMtRDrmpQMDimpPuQKM96cRx1pO1GOKXMx2KWq2MWqadc2NwcRToULYztPUN9QQD+FeIyQy213NbXS7J4XaORfRgcH617yw6V5h8UbMWmtW9+oO29j2v/10QBfwypT8jXpZdWam6d9/z/4b8jWk9eU5hgdhOKy5gyNketWzcOw2qM1GYHLbnBr2lJrdnRFWCGdkXB6GmvknIxipAnY9qk8sAdKak+jG0rmfOuBuFLCywWysq/vQxbcOvpxUkq8kfhVnTUWSN4y205z6cf5zTlLS5qvhMvV4YrfURHbY8sIM46A88enTHSrMOySMAYzVjxRCI76FgzOrRA5IOOp6fgRVGAhGHoeKcZOUVqcqnys7P4eeJIfD2pSWWqTCHTb3BErE7IJhwGY5wqsMhmx1CEkAEib466CImsteVCpH+i3fAAyP9W57lvvKTzwqDjbzg/ZI7uLdkE44z0qzLqyPpQ0LW/Om04IERA/+rAzj3wOw7fhiubkca0a1Pfqu6CULS5kchb3sctsqptKgYzUNxFDeKYU5lPIxzzVrUfA8VrI01hq84tM4RJItzZI6bgRnof4RxWKbn+zLpluElbjAcDAz3FehCSmrwZat0Htp1xGCAobjOVNSl7SW2eBnYTLn5h6j07VeaZfI818+Xt3dOoqGPQrS53ul4sG7nBAYZ/Ein7TT32NtdTno2c3kSYZsuB8vU884rQ12ykQJMBujAwSP4fc+3vW3pWlRWKySCYXL7vv4xtHp1PvXPapdarHqUkAbCNny1VVIKHgHJ5zVqpzS0Y1rsQWkFvcQtul2TqcjP8xWpY3hjRUmUSDsy9aW1tYILYz3qlCOWLEjH5Gpo7eKRfNhYMuNwyeKpzuO12WTp8FyrMRgHrjjrVaPSkt1cRSMc92Pb8KtxGLeVicNtAJCHI/Oo791KACQLgg9M1nFzva44tbMsW7Cwj5z5pOfxqGd55W82UkKT1Y9aYoa6YbccLuyeB71HeSLPKojdvKQYC5yCfWrSa6iVy/Z3kSfKFZh3yal1HULe0GxclnHQD7v1rJjumtnBiTdkjIPcf0o15PtRWVC4Ykgrnp0x/WptrqFlfUvNGXsWuYFJQsFLhOM47n8R+dZFxCbpNhUH0IXmur8Pus3hxLQEhVVhg85O4tmsTUZRby7UX5sHacYrCMndrsLmexgraXCTqI9/B4wK6Hy50hM0jbEUcueAfXmk0lWO2SZTljwT3FXPF8hexgijbERkyw25zxx+HX/ACKJzlzJCOdttOke6uroqJS52Rl3/wDHv5cVnJazJv3gFycHPJrpIXMNmyxgbgpKnHf1xXN2RuVvYw4Rm35z1zjmqU3rqP5GroWkNJNmQYAOSQOvoBXWXco0q28xInl2hQEB56gdfbrWzYaUIdPjnmXEzKpKnsP8a1vCiQnXozMoJRSyZOOeB/I1w1a8tXvYG0otna+CLNrTRIWmj2XUvzyZGCM9FOemPT1zXRgd6jgA8sYAHfiph1r5+dRybbe5x76iAetIV7nrTsikPJpKTBnKeP2mS2sTH80W99654Jwu04/76rixcGeQKgrt/HkrrbWkKDO9mY8ZxgAf1Ncdbwm2l80jBIxivWwsn7Jf11OqlbkuWYtpTy8fN610nhbSmMn2mYghDhQB/F/9auVQmS7i2BjIzgKq9zkAD9RXp9jb/ZLSOHO5kHLep74rnxVVxVk9yarsiygHc0EULilOCa4Ly7mGhGwOM0wgHrUpqI5B4p3l3Jdhm0UUu8+lFT73cehGvXAqQcVCuccVKhIqLEXJRSN0o96RievGKXUdyNh8p55rJ8U6QutaBcWm3dOv76DjJ8xc4A/3huX/AIFWwPWkDYOaqEnGSknqgTa1R4fDCqoGXGOoNTBQVJPStbxOiaf4nvoUj/0cur7cdNyqxA9gWOKzrhdiBoiHjboR/KvoVLnSkup1811fuZMwKvlV+gpr7sdMVPPKkPMpCr61Unvbd9ohmjkY8fIwNbxK1uVnb94ajjkAkIz1qR0wcnqarRxmW9Kj+dadDogaOqIDp8L/AHicDd7YrHTeSRnA9e9dDLpd1Bp5aZCIWOOoOD74+lYdwDHkYwaKUlJaM5qkbO5d0m/NvJ5cjHbng9hW9qkEOp2i+WgWeMZHoT6fQ1yMCt1YYBNatncvABhiV7c9Ktxu7ozT0szj7r+0rTUFSed0iDEFW5H09qt2d4huAxIkHX/69dPfR22sxmG5Lkn+NCAwx6cH+Vc7q/hC7+z7NNuPMBHIY7D7j6fj+Fa+0jtLQ2i+YsjVraSUx3Ee6JsKCeQc+oqO70q3uA0tpLtWQjgdiP8APSsrTNJu9Dc/akUpJgfIchSef8/1qG5W/wBNvLi5tZGa1lGQXJKqSemOxHOD6fjVQSb9xis76EJ0+9s7hvK3IwyPNjbbx9RyKt3cF5HILqV/MIxh2XP4Y7Vq2YaSwuI7mVjIWJXceegxz9c0yfU49OH2eWN2L/xDGMfj15/z0y+ZvQd7bEN1Kup6QVIEcqsC47DgnI9un+eSmmmT+zJIo8FUXOfT/OKuaLITvIiaOM4C5AwaSQyxTt9mhTyHxvC9evpn60be6T1sVdHCx33ztljkAD6Z/kDTreymm1eTBbyj83Hf2/z6Va/siOW7WcSMEQ79gHUjpz9a6HR0c3qIqfK2A3+NJ1Fqxx2bI7u3j0zRnaVB5k/y7T6Y6VzNlbI28lyQrYAyP1rqfFEqXUiRqwKICBznn1/z7VhWFnFBJI2ck9SeMDrShJ8moKV0RmLDZQDr3q5DbwzsrM3zff2+1Q/a4grlSCFz1FZpnaB/tEbAgfLQ02gSNLSPNt9eazOREASCBjccA5rUurZZJQroGGDjcuRXOxX7vfxXe0oqr68Zzg/UYrrtb22Omi5bIkOFxnOD1rOafMrlSWtzntY1EW4jjgiLux+Y+n/16parcP8AaLa2curn5jz15IH8jSiUSzwtEN3IJycYqDVH3aiknpgD2/yc07JOwWdyaaYW8LO+NkaktzmjwwkN7cpdCMfKx3Z5APp/Ws3XJSLkKv3SgJUdOp/+tXRwAWarDDGsfOcKMUp2UdOoPbQ9Eu5oms4mjx1HA6DjpWZDfQ298HiYGVf4c1k2olCAMSSei5rQsLGyhle5vmZpQPkiBzz7/wCB/wAK4XFRVtxwinH3j1/w9ff2hpEFyQQzZB464OM1o5A61zvgzUlvtKPyhJIpNrIDnjAwR7dR+Brfz+VeFVjabRxyVnYdUc00VvE8s7iOJBlmPYf57U/cMcVyvi7UEMi2qOGEfzS4Ofm7L+Hf6+xp06bm+UUVd2Of1PU5b7UJLiddu75VQHOxR0H9T7kmqMkzSSozZ8sfw+tQ3lypcBUGA2c9zT5kkSVIzzx2r11FRSR2WsrI3/B9mk+ui6KnFshZeeATwM/mfxArvRzWN4V01tP00mZSs8x3sp6qMcD2Pt71tCvIr1OepdbHLUfMwLBeuaUnjIpDyKTOOKxZCFJqF2walGe9VZ+M0ITF8yiq+aKegEqcCpAeM1ChqQYqE0RYmU8CgntTFNOOMUrjQ0HmmseeKGqA53VSkTYo6joNhqbyS3aN5rADzEbawx+h9OQePwridZ8OXmmFvKDXVqcESouCD6MvOP5HjvwPR8nGaXGV9Qf1rqpYmdPrdFxnKOh4Jr8Qn0yTkhlwwI781wtnPJFeLg4O6vZvH2lpHfSpEmxLhd4x0B7nH1ryDUtOurXUNojY7iCpAzmvew1ZShc9Cg1M6uOUSwq/qM1RlDxyb0JDA5BBqxZQywWgSVcHrjuKc6B1Oau5pB2Z0Gj6nLNoU1vM4ZpCV3FcsuPfNZlzZhlAlIBxwRVG1ke2kypI9R610Fk8GpXMFqz7ZZWVI/qT0rHWDbWwpxSu7aGLLbNbxEtkr2NVDIApAxXaa14fudIZvOUy2rdJNvy/Q1y89hE7HyWMY7DqK3pVoyV1qczjfWOxHafu4zIx+Yn8qvw3jAZ7euazGhlh+R8H0K8g0qxuV5zg1q0nqEddDSlurO7UxygHP94VBeWG21ZocsmDwOtZ4j2HFaWl3eP9HlPyk/Kc9KVrbFO632ObkCE/uGztUAkHv71BfkNbZnXcU5U4yQataiBo97LvRZVlYEDOOP8A62aigdZ9rOAFYnABzx2rRSsrl+pLaaqW05Ay4m55/ris+XUbizlWYkSIcblYcN7Z7dT0/WrCaZM1yTFKv2cckE/MParE2jpdo0YlZFwMZGeR3qlKKItZm3ayw6hbRXNoWCOOQw5B7g/StHXPN0zQS1v8s8zLEzA4Kqckke/AH41k/D6A2qX9tep/qXypxkNn0/74/Ws3xV4iuLzUpLeWMQ2sBARByTwMsT3/AKfnWVuapyrZD391AxuJLbcvUjqaiEMsURkZm+c4IHp71X0TU2uruS1EWI1QyK2enIGP1q/dS7clgQo6Z71tJtOw46aFM4SMjue2KT7Qtrau8yMyn7oGOf8ACq894TnCM2Dx6Vkm5urq7McgCxjIC7eAP6miytqaqm36G/ZSQ31woTCJnkHqPaut19VvdB+zLt81WDIe/HauIjs3SYPbsA3HHQZ9a6wuz2/GPrisZvVNETjZ6HK6XKIbli2SuMEA1l3N3cXF2zIMhmO1MdB6VqGweOdxHEQvbGaSz0iRbhpJGUJ2z1qnNDjdvRFqygE0kJlAYoQcnmt8hQ24c456VUtkRVG0AAdSao3+uxwF47dC7KcFj0rBu5pyxgryN+G5dXHzYarsJO4EtXC2uoyTThmJyTXVafLJJGB68c1EoroTdSV0d78Orwya9PapuKfZ2kbGMcFRz+LdvX616Up4ryz4a/uvEF1ldzm1Ycc4/eR//WrZ1jxjNBdtHZxRvCjEOxJy3Y47D6815GIpSnVaicM7uR1Gu6qml2ZYEee/EYOOD6n2H6156jeZKxZyxOTknJJqbxZerew2tzFKzpz1HTIHX34NZOnz/Pzg+9b4ekoQv1NaUdLlq4jG8Y6n9a6rw34fk89J76NTDGo2I3IdiPT0H5HpzzWZpOmtqV5CqqCoIZmIyAuea9GAHYYA6D0rnxNZr3IhVnbRBz16mgHmgdacFz7V5uzOcVSKQjJ4oHHSgEjrVAM5PBqF161OTmonXHIoQmivs+tFS80UvmBCo6U/GKjU8cVKo45rJIm49TxyKcTj/GowTmpM5FMZG/PSoWODU7elQkcULQTFQgjFS/w8VCBzUoIAq9RIx/E2kf2tYARbRdQktFnA3eq57Z/njNeWalbsCcoVkjJVlYYIOeQR6g9q9qJ5rlvF+gPdlr6yUvPgCaLrvAGAy+4AxjuAO/XtwmIUHyS2Nqc+V2Z5TI/ODSHBXIxWhe2QYbl+U1nmNkG1q9uMk1odiZAQW6Cm4kgkjmhcxzRsHRlOCrA5BB9QRVuNAB7miWEvGdp5pqVjVSPd9H1K31zRre/hjXyLpMtEw3BW6OhyOcMCM4wcZ6YrhfiD4Fknha/8NoVlUl5rGPgOOcmP3/2O/bnANT4UawthfS6TcsFgvXDwk4AWbGMf8CAA+qqO9eqHrkda8aXPhK3ubfmjzqidKTS2PmiO+IXLEHHXJq7Z3tveqfLK7x1Arr/ip4Jke7n1vTQTazEyXkSLkxN/FJjup5JPY5J45HnGp2txp+lA6PkzhsMxUMTn/D+le1SrRrRUo/8ADGqaaTNueDoV/KnWltHGfOndVxzgkAD3rnzrEiQwwXErG7Cr5jqu1c4GT/kY+gqhqK6jNshj3sWIzhuufU8VtFPZlpXLHjKQ3l3DPDkwIojVs/eIJJOO3X9Pwql5lvJowTeqXCZwuQM4xg+/T86NQspbc2iTsrhCzcAtnPb/AOtVW78PXEwjaNsOQMgg9a2TSS1NY7I0dKuTNYLGxbeuQdx6gdP8Pwqyl3PJfWywHYCyBvl65I6/hUOlWD20yxSwjzAMnHYfSrUlnctexSWajcHBO88DHc+3TNLmjfUhnXXbRWUCGHnqW9wP/wBdcbr6f2pqEjx4EFvGAz/dHckkn8R9BXWXUbTQkHOCMelY11pf/EnurW3cxzz8tJ/e56Hvg9PxP0rGnKMX5ihsZPha8tTaXSxKVKMpc7cFxg4+vRuvrVT7a9+JGl+RlI+XsM//AKqtaJ4dutPuJHnmjMbpt2RFiCc8ZyB05/Otm10ZIGdymWYg5I5FaOSTbNI2TujEgw0JHGQe1Txw7jk9fWt220tVZjsDZPcZqyLGNQfkCn1FS6iOhVW1YzLWERx8LyetadpFthPmcZPSnpGIwePxqlqlwLaFpW6DpWbdybhqM8cI2jHPbFYF3fEHCsT6gV0+h+Dtf1yzjvZ7Ge0tZGCqZcI7A4+cBudvI5wc9uOav/FK38LeBPDOnLDbW9/q14CUcS7js28ytyRjcVAHGeeeOcViINqENX5GFTExpuyOe8K2N3rxnCqsdvDgySNx1zgD1PH+elcp411Ww0a5W3gia5uicSIrYC9uTg88dPzxxmg3jnU3jkh0+X7Ajqqt5Bw7KO2ew+mD74rAubbAM824Fsncx61qotvVnLLESlqtETtr9xGFuVRQASShyc+xr1b4c3ttrU5XcyqsXmAHAP3lHP8A31Xh2HupAsZ+UZx3r0L4bQzWi3MjZVAAg44OTnj6Y/Woqq+iLouTPSPC93m4uriXkqmTg468/wDstPhug48sj7vWoNPtVjtZJAMeYc9McdqqW7sb4IqknNZOKbbNeVXZ00tl59phGUjHJB71a8P6FcXs/kWw6YLyMPlQep/wrT0DTX1EfZ4ht/56SZyEHqf6DvXoWnWMGn2iW1quEXqx+857sT6/5HHFefVxLp+6tzF1HHQZplhDp1qsFuDtHVj1Y+pq0f1p5XmkIwa85tvVmVxvajtQc5pQPes+oCZobk07A9KMY9aLBcjbI6VEzVM3SonwatEtiZ9qKbhfWiloBRVjViIkjJqJQM4qdE4rK5Nh9OB496YF9KcF9aLjsxhOM5qIt5ZOBuHpU5Udc0wqAetCaE0xqNu56GlPWjHOc1S1rU7bSLP7RdHcxOI4lPzSN6D0Hqe3uSAdVHmdkJJ7F056UoNecR+NdXW682WK1eE/8sAhAA9mznPuc9eldtoeq2+s2nn2xKumBLEx+aMnpn1B7Hv7EEDWpQnSV2VKnKOrF1TSLLVM/a4f3n/PZOH7d+/AxzmuK1fwddQBmtwLuIf3B8//AHz/AIZr0gKMc0qjFFLETpaReg4zlHY8MktnRioBODgjHI+tCDaMHg17PqOj2Wondcwgyf8APReG/Pv+NcrrHgyXBeyHn/7IIRv14PbvmvSpY+nLSWh0qqnvoefyRg4aNijgghlOCCOhB7GvZvCuq/2zoNveOR9oGYpwO0i4yfxBVv8AgVeZnw/qJJUabqAH/Xu/+Fdz8PNMutM068F3G8XnShkRxhhgEEkds8fl9MrGzhOF09UTWs43udQCVYFSQRXK614LtbuVp9MMdlO3WMLiI+4AHy/hke2cmuvVOPegLivPhVcHeLscyTR4vqfw21OWOVlsFaXayrKssWcE56A/0z9a5nTvC9/ppmS+XbOXxsbgqBwP/rV9H4qrfada3yAXduko98g/mOa7aeZTWktjZTfU8H0zRJVSL7YBc3TcBVXPPoAOp+n4etdFL4du4bYTTWEiR9yFGQPfHI/GvWNP06zsExZW0cJOQWAyx+rHkj8atFBnJpyzFt6L+v0LdXsjwd9P/eFo8Dd1NMa3htz8xUE8kk4r3b7JAMhIYgD1G0c0+GGOBcQIkI9I1Cg/lTeY/wB38f8AgDVXyPDID53yQI0zf3YwWP5CrC6XeO3zaXedec2z/wCFe2l3zgux/Gl5Izk1LzF30j+I/bX2R4g9kIn2G1dJuPlMbBufY1ZttJ1O5IWDS70q3Rvs7Kp5x1IA/WvaldgmA7BfY0mSepzTeYy6IXtn2PIY/CWuMQTYbV9TNFn8t2aVvBWryNzHGo9N2TXrm0GkVcdBUf2jU7L+vmP28/I8sg8BalJIBJHHAgOcyTIR/wCOkn9K7Hw74U0/RplufLS4vVOUlZeIyf7oOeffr6YrpNvXBpu0YrGpiqlRWb0M5TnLc8P/AGivE+qWxj0K0gMNhMFmnnyc3HfZxj5Aeo5yVHTGD86+L7yOW3t0iVUlDMxCLjIPc9+38+lfY3xi02LUfh1qzPbtNPaItxCVJDJh1DnjtsLE544z2BHwzc3LNOzSHMh657V0Rr2opR06fPv+JMIrYjjjmWXzzwEILHNXLi8SZmeRhjpj8MVQlld1Ks3B7Cq3Nc9PFyw7fLrfubygmbeiXax6imFJUdulez+F4o301Jc/fYtjufT+VeGaXkTjYuTnBr3HwepfRbXGQQDlfTn/APVXfhMTKu25nRThZaHWWjbrYo5ynQA1f8O6Rc395iziaQoQC+MKp68noKi8J6DNrerLB5zQWUeGuJlGSFPQL23HoM8Dk84wfa7G1t7O2itbONIbaIbURTkD8e5PUk8k8mlisSqXux1Zyzm4uxDpGnxadYR28QXP3pGVcb27n/PpV7A6UbQD70uK8hu+pha43HrQeafwQKYwpXQWG4/Okx707Aoxz1qLobQo4X1pHP504CkZR60BYiaomxUxUYqJh3zxT5hNEeKKTzf9g/lRUadg+ZXHrUiZ7VGOtSqeOtC9DKyH7uc4pSflpopSaL+Q7IjLHvSA5oJyaUY+lLm8ibIUEjgda808eTFvErozEhIowB/dBGcD88/jXpJIFcZfeHn1TxfdXdzkWZ2scDliqKoX/wAdz/8ArFduGqRhK8trf5F0rKV2cssJCb2yFPQnvUmn3E+n3q3VlIY5RwcjIYd1I7j/AOsevNbXiPSb1tSH2SBpLcjCLGPunqay7rTL61wbi2kjHrwR+YyK7oVoTWttTpXLJHpelahFqVil1CNu7h0zko3dT/nkYNXh0rzLQ9Sk0y68xBuRhtkTsw/xFeiaZf21/CXtZQ+PvLn5l+orz61L2bulocs4crLY6U5femk8U9Rxjv1rnv5Akgbp7/WobSWVpJhJCYwrYU5zuHrj/PWrCjtTuhq1LpYXKhykgZ9aTnkmn0m3vVt6bBZDM5pV69KVVzThwaSdug7Jig96N3alXHelJGQPWk5eQ+UQZ/CkLYJyRTyOKYUU/eq1LyFyoVWVjwcinYzSLGq9KeBUc3kUojCOelJ1PFSgDNMC4Jp83kCiiNsqc0hJIqLVHlh0+4ltkEkyRsyKTgE47mvGdV8T+I2nYpqN1EVJG2PCKMZ7AY7/AMvSuijh3WTasrAl2PcEjkZMqjEeuKxpPEWhq5Q67o/mA42/bos5+m6vnXxB9r1pWOoXElw+7cQ5zknvisuxijgZ43AVsAYxjpXXHApL3tSnTZ7J4/8AiRpMekX2l6ay3k91E8E0hysUUbKQxzwScEgenXsAfjPUIFiuX2MShY7SfSvSfGFu8bKRIxjYcLn+leeXkTBnaXIGc1vUw1NU+WKHTTi9SgkZdgM/iae8JA4ArrrvwJqek6NYahq6PaG/QyW8TAbinGCwzlc5BwR0I98Z0GnAkQ7S7scDHWuOnh1yuLW/U6bx3uN8KQxJqC+aGbcpAwOh6/0P6V7l4QsJLuGO0so2munkKhF4yf6ADqelYPww+EWt6wEvisdnYscfbJ/ukAjIjUfM55PopKkbgRivpPwf4X07wrpa2mnpvkPM906/vJm7knsvooOB7nJJGusPHlsr/wBbjdaKWg/w3ocWiaNFZI3mPuMksgzh5D1Iz0GAAPYVrqgUf41IFGKNvGDXDKbk23uzieruyFrqJGwW59KlWQMMjFQSWiO2do3VKsWwDBpRk+wrIduweKNxzzijkUhHzZpt+QWDI7GjcewpACCfSl6ms7rsOw/ORyKADiminjpSbKSRE55wahbpwKnkx/SoH6e1NPTYTiiPHuaKXcKKV2KxTX9aeG7VW3cn1p6k96mJlcsA9jSljtx2qIHJNPzTY0BOTSc0FgRnFJu44oS1E3oIWyMYNIpUE+tOzTR1561ZNxwVQ27HzU4BGUq6hlbggjINNz0xTqaQXObv/DQe5aS0dFjbJKPxg+2B0/w/LHvdMvtMcXCLIoXkSxH7v4jpXe56c0DFbQxE1vqaKo+px1h4ru4sC7jjuU9R8j/px+nrXVaXrFrqGFiYrKeiOMH/AOvTZNNsps+baQk5zkJg/mOarDQ7RLhZLcNEQQcA5H/1qUpUp9LDvE3lPc04NmoFJwOcmnFgKzsiLk6nNLuxUKtjmlL5FUwTJQwPSlLY61AGwaVmpIq5MWGODSq2etQfrT0bik9WNE+7A603OTk01T69KCfQ1SES7/wpQ3QVDnNKCc8VOzKvoT7sdaTcKgdjmgE0bhcnO0kggHI6VkTaBpkrMz2wYMT8pbK8+1aYH50jHBxnmnzOOzKTOUf4f6HvLK1+noqzKQPplSag/wCFYeGnuDPMl9NJjA3XAUD3+VRn8c12WMtTg2OBxWirVf5mDk7nnWr/AAf8M6pEY7i61hF3bl8ueIFPYExHjtzmneFPhF4R8Nagt9Da3OpXsbB4ZdTkWUQkd1RVVM98sCQQCCK9CJFR03Xqtcrk7D5mZniTQNK8TWBs/EFjHfW5YOA7MjKw6FXUhlPJ6HkEjvWHpHw18F6ReLd2Hh62FwAQGnlluAM8H5ZHZf0rr6TGOaz5pRVk395Kkx5dnO52LH1JpR0po47CnKcVnbsFwDegoU/NzSDHfFDdOKaQrjs88UhPPWkB4phPNWloK4/NJmoy/IANOB460rBcd70FscU2RuOKhOT61myrk4alycc1CjYp27jrSeg0wLAZB71C7fMR705m71AX56URQmx3HvRTdxootIVzMzzUitxn0qqhPc1IAQM5pIyLasOKUktwDx9KhjbIANPPPSqAXPy0qGohz06U4cdKaJZKSMdaKjpxyFz61T7iQgbnGKeSajU5p556UIY/qvHWgNj60wnb3phY5poRYMlCN3qFDnr1p2aRSLCkE5pSQaiU+lKDzTQXJg3FKDiog1LnJ4p+YXJM80oNRgjBBoyQBjpTSHexLn3pS3FQl6VW456UWHcnD8CndVqAOBTgTTs+oXJfalD4x3qEvzinZIxiptqUmSbs0oNRDPIFN8wBselOwXLAb3qN2O4EGgOCM00nmi2g7kofj0pfMyarhucU/OBSSuFyTfzzQWFRhvWjOTTtrqFxyuDT6i7HFKOlDQrj8j1oB/OozzRnA+lKwXHBvWlLYHWo88802RsU7Bck3UxmyaZu4pRyM04oTYp9aVX+aouS3FPA4oAkc8YFR8jnrQzc85oY9hWVmitxUOTzTjxUROBx1o3+tDGhXPWq8jfgKkZs1CxyaaQmxMiik2UUrAf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A whole-mount section through an endobronchial exophytic squamous cell carcinoma of the lung.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_14_40170=[""].join("\n");
var outline_f39_14_40170=null;
var title_f39_14_40171="Relevant info from RADS subject";
var content_f39_14_40171=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Relevant information to be obtained from subjects with possible reactive airways dysfunction syndrome or with asthma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Was the onset of symptoms related to one \"memorable\" event in which there was exposure to a gas, fume, or dust?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Were there repeated gas, fume, or dust exposures of lesser intensities that still forced the subject to leave the premises?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Is there any ongoing exposure?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        What was the nature of the substance? Has it been previously described as causing RADS (eg, acetic acid, ammonia, chlorine, isocyanates, mustard gas, fire/smoke)? Absence on a list of agents causing RADS does not exclude the diagnosis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Was the concentration of the offending agent likely to be above accepted levels?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Were other workers or persons in the vicinity also affected?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Were there ocular or nasal symptoms? How long after the exposure(s) did they develop?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Describe the timing sequence of onset and diminution of symptoms: eg, immediate cough, shortness of breath after 30 min, wheezing after 1 hour, etc.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Was there a visit to an emergency room or a physician's office?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Were lung function tests, blood gases, or chest radiography performed soon after the event?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Was treatment initiated? What medications were used? What were the dose and duration?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Were there subsequent assessments, including records of symptoms, chest auscultation (wheezing), spirometry, bronchial responsiveness, and allergy skin tests?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_14_40171=[""].join("\n");
var outline_f39_14_40171=null;
var title_f39_14_40172="Causes of postoperative fever";
var content_f39_14_40172=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F69959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F69959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of postoperative fever",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infectious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surgical site infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumonia (ventilator-associated and aspiration)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary tract infection (usually with an indwelling bladder catheter)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intravascular catheter-associated infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antibiotic-associated diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sinusitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Otitis media",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parotitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intraabdominal abscess",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meningitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acalculous cholecystitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transfusion-associated viral infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foreign body infection (orthopedic hardware, endovascular devices eg, prosthetic heart valves, grafts, and stents)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osteomyelitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endocarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Noninfectious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Surgical site inflammation without infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hematoma/seroma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Suture reaction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Thrombosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Deep vein thrombosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pulmonary embolism (thrombotic or fat embolism)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Inflammatory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gout/pseudogout",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pancreatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Vascular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cerebral infarction/hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Subarachnoid hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Myocardial infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bowel ischemia/infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug/alcohol withdrawal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Transfusion reactions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Transplant rejection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hyperthyroidism (including thyroid storm)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypoadrenalism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cancer/neoplastic fever",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_14_40172=[""].join("\n");
var outline_f39_14_40172=null;
var title_f39_14_40173="AGAI management GERD 2";
var content_f39_14_40173=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    AGAI management GERD (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        What is the role and priority of diagnostic tests (endoscopy with or without biopsy, esophageal manometry, ambulatory pH monitoring, impedance-pH monitoring) in the evaluation of patients with suspected esophageal GERD syndromes?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade B: recommended with fair evidence that it improves important outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Endoscopy with biopsy for patients with an esophageal GERD syndrome with troublesome dysphagia. Biopsies should target any areas of suspected metaplasia, dysplasia, or in the absence of visual abnormalities, normal mucosa (at least 5 samples to evaluate for eosinophilic esophagitis).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        II. Endoscopy to evaluate patients with a suspected esophageal GERD syndrome who have not responded to an empirical trial of twice-daily PPI therapy. Biopsies should target any area of suspected metaplasia, dysplasia, or malignancy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        III. Manometry to evaluate patients with a suspected esophageal GERD syndrome who have not responded to an empirical trial of twice-daily PPI therapy and have normal findings on endoscopy. Manometry will serve to localize the LES for potential subsequent pH monitoring, to evaluate peristaltic function preoperatively, and to diagnose subtle presentations of the major motor disorders. Evolving information suggests that high-resolution manometry has superior sensitivity to conventional manometry in recognizing atypical cases of achalasia and distal esophageal spasm.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        IV. Ambulatory impedance-pH, catheter pH, or wireless pH monitoring (PPI therapy withheld for 7 days) to evaluate patients with a suspected esophageal GERD syndrome who have not responded to an empirical trial of PPI therapy, have normal findings on endoscopy, and have no major abnormality on manometry. Wireless pH monitoring has superior sensitivity to catheter studies for detecting pathological esophageal acid exposure because of the extended period of recording (48 hours) and has also shown superior recording accuracy compared with some catheter designs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade Insuff: no recommendation, insufficient evidence to recommend for or against",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Using alarm symptoms (other than troublesome dysphagia) as a screening tool to identify patients with GERD at risk for esophageal adenocarcinoma.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        II. Combined impedance-pH, catheter pH, or wireless pH monitoring studies to distinguish hypersensitivity syndromes from functional syndromes, the distinction being that in hypersensitivity syndromes symptoms are attributable to reflux events, whereas in functional syndromes they are not.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        III. Combined impedance-pH, catheter pH, or wireless pH esophageal monitoring studies performed while taking PPIs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        What are the unique management considerations in patients with suspected reflux chest pain syndrome?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade A: strongly recommended based on good evidence that it improves important health outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Twice-daily PPI therapy as an empirical trial for patients with suspected reflux chest pain syndrome after a cardiac etiology has been carefully considered.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        What is the best initial management for patients with suspected extraesophageal reflux syndromes (asthma, laryngitis, cough)? What are the unique management considerations with each? What is the appropriate dose and course of antisecretory therapy in each?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade B: recommended with fair evidence that it improves important outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Acute or maintenance therapy with once- or twice-daily PPIs (or H2RAs) for patients with a suspected extraesophageal GERD syndrome (laryngitis, asthma) with a concomitant esophageal GERD syndrome.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade D: recommend against, fair evidence that it is ineffective or harms outweigh benefits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Once- or twice-daily PPIs (or H2RAs) for acute treatment of patients with potential extraesophageal GERD syndromes (laryngitis, asthma) in the absence of a concomitant esophageal GERD syndrome.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade Insuff: no recommendation, insufficient evidence to recommend for or against",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Once- or twice-daily PPIs for patients with suspected reflux cough syndrome.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Does GERD progress in severity, such that symptomatic patients without esophagitis develop esophagitis and Barrett's metaplasia, or are these distinct disease manifestations that do not exist along a continuum? If patients do progress, at what rate does this occur, and does it warrant endoscopic monitoring?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade D: recommend against, fair evidence that it is ineffective or harms outweigh benefits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Routine endoscopy in subjects with erosive or nonerosive reflux disease to assess for disease progression.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        What maintenance therapy is indicated for patients with the typical esophageal reflux syndrome (with or without esophagitis)? When and how should antisecretory therapy be decreased or discontinued? What, if any, risks are associated with this?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade A: strongly recommended based on good evidence that it improves important health outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Long-term use of PPIs for the treatment of patients with esophagitis once they have proven clinically effective. Long-term therapy should be titrated down to the lowest effective dose based on symptom control.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade D: recommend against, fair evidence that it is ineffective or harms outweigh benefits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Less than daily dosing of PPI therapy as maintenance therapy in patients with an esophageal syndrome who previously had erosive esophagitis.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Kahrilas PJ, Shaheen NJ, Vaezi M. American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease. Gastroenterology 2008; 135:1383.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_14_40173=[""].join("\n");
var outline_f39_14_40173=null;
var title_f39_14_40174="Ventricular thrombus HES Echo";
var content_f39_14_40174=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50869&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50869&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ventricular thrombus in HES",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Echocardiogram shows a large apical thrombus (arrows) in the left ventricle of a patient with the hypereosinophilic syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_14_40174=[""].join("\n");
var outline_f39_14_40174=null;
var title_f39_14_40175="Stroke treatment delay and outcome";
var content_f39_14_40175=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F66764&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F66764&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 639px\">",
"   <div class=\"ttl\">",
"    Stroke treatment delay and outcome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 619px; height: 497px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relation of stroke onset to start of treatment (OTT) with treatment effect after adjustment for prognostic variables assessed by A) day 90 modified Rankin score 0-1 versus 2-6 (interaction p=0.0269, n=3530 [excluding EPITHET data p=0.0116, n=3431]); B) global test that incorporates modified Rankin score 0-1 versus 2-6, Barthel Index score 95-100 versus 90 or lower and NIHSS score 0-1 versus 2 or more (interaction p=0.0111, n=3535 [excluding EPITHET data p=0.0049, n=3436]); C) mortality (interaction p=0.0444, n=3530 [excluding EPITHET data p=0.0582, n=3431]); and D) parenchymal hemorrhage type 2 (interaction p=0.4140, n=3531 [excluding EPITHET data p=0.4578, n=3431]). Thus, for parenchymal hemorrhage type 2, the fitted line is not statistically distinguishable from a horizontal line. For each graph, the adjusted odds ratio is shown with the 95% CIs. CIs from the models will differ from those shown in the tables because the model uses data from all patients treated within 0-360 min whereas the categorized analyses in the tables are based on subsets of patients: the modeled CIs are deemed to be more reliable.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Lees, KR, Bluhmki, E, von Kummer, R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375:1695. Illustration used with permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_14_40175=[""].join("\n");
var outline_f39_14_40175=null;
